

NATIONAL QUALITY FORUM

Measure Evaluation 4.1 December 2009

This form contains the measure information submitted by stewards. Blank fields indicate no information was provided. Attachments also may have been submitted and are provided to reviewers. The subcriteria and most of the footnotes from the [evaluation criteria](#) are provided in Word comments within the form and will appear if your cursor is over the highlighted area. Hyperlinks to the evaluation criteria and ratings are provided in each section.

TAP/Workgroup (if utilized): Complete all **yellow highlighted** areas of the form. Evaluate the extent to which each subcriterion is met. Based on your evaluation, summarize the strengths and weaknesses in each section.

Note: If there is no TAP or workgroup, the SC also evaluates the subcriteria (**yellow highlighted areas**).

Steering Committee: Complete all **pink** highlighted areas of the form. Review the workgroup/TAP assessment of the subcriteria, noting any areas of disagreement; then evaluate the extent to which each major criterion is met; and finally, indicate your recommendation for the endorsement. Provide the rationale for your ratings.

Evaluation ratings of the extent to which the criteria are met

- C = Completely (unquestionably demonstrated to meet the criterion)
- P = Partially (demonstrated to partially meet the criterion)
- M = Minimally (addressed BUT demonstrated to only minimally meet the criterion)
- N = Not at all (NOT addressed; OR incorrectly addressed; OR demonstrated to NOT meet the criterion)
- NA = Not applicable (only an option for a few subcriteria as indicated)

(for NQF staff use) NQF Review #: 0013	NQF Project: Cardiovascular Endorsement Maintenance 2010
MEASURE DESCRIPTIVE INFORMATION	
De.1 Measure Title: Hypertension: Blood Pressure Control	
De.2 Brief description of measure: Percentage of patients aged 18 years and older with a diagnosis of hypertension with a blood pressure <140/90 mm Hg OR patients with a blood pressure >= 140/90 mm Hg and prescribed 2 or more anti-hypertensive medications during the most recent office visit within a 12 month period	
1.1-2 Type of Measure: Process	
De.3 If included in a composite or paired with another measure, please identify composite or paired measure	
De.4 National Priority Partners Priority Area: Population health	
De.5 IOM Quality Domain: Effectiveness, Equity	
De.6 Consumer Care Need: Getting better	

CONDITIONS FOR CONSIDERATION BY NQF	
Four conditions must be met before proposed measures may be considered and evaluated for suitability as voluntary consensus standards:	NQF Staff
A. The measure is in the public domain or an intellectual property (measure steward agreement) is signed. <i>Public domain only applies to governmental organizations. All non-government organizations must sign a measure steward agreement even if measures are made publicly and freely available.</i>	A Y <input type="checkbox"/> N <input type="checkbox"/>
A.1 Do you attest that the measure steward holds intellectual property rights to the measure and the right to use aspects of the measure owned by another entity (e.g., risk model, code set)? Yes	
A.2 Indicate if Proprietary Measure (as defined in measure steward agreement):	
A.3 Measure Steward Agreement: Agreement will be signed and submitted prior to or at the time of measure submission	
A.4 Measure Steward Agreement attached:	
B. The measure owner/steward verifies there is an identified responsible entity and process to maintain and	B

update the measure on a schedule that is commensurate with the rate of clinical innovation, but at least every 3 years. Yes, information provided in contact section	Y <input type="checkbox"/> N <input type="checkbox"/>
C. The intended use of the measure includes <u>both</u> public reporting <u>and</u> quality improvement. ► Purpose: Public reporting, Internal quality improvement Accountability	C Y <input type="checkbox"/> N <input type="checkbox"/>
D. The requested measure submission information is complete. Generally, measures should be fully developed and tested so that all the evaluation criteria have been addressed and information needed to evaluate the measure is provided. Measures that have not been tested are only potentially eligible for a time-limited endorsement and in that case, measure owners must verify that testing will be completed within 12 months of endorsement. D.1 Testing: No, testing will be completed within 12 months D.2 Have NQF-endorsed measures been reviewed to identify if there are similar or related measures? Yes	D Y <input type="checkbox"/> N <input type="checkbox"/>
(for NQF staff use) Have all conditions for consideration been met? Staff Notes to Steward (if submission returned):	Met Y <input type="checkbox"/> N <input type="checkbox"/>
Staff Notes to Reviewers (issues or questions regarding any criteria): Staff Reviewer Name(s): RWinkler	

TAP/Workgroup Reviewer Name:	
Steering Committee Reviewer Name:	
1. IMPORTANCE TO MEASURE AND REPORT	
Extent to which the specific measure focus is important to making significant gains in health care quality (safety, timeliness, effectiveness, efficiency, equity, patient-centeredness) and improving health outcomes for a specific high impact aspect of healthcare where there is variation in or overall poor performance. <i>Measures must be judged to be important to measure and report in order to be evaluated against the remaining criteria. (evaluation criteria)</i> 1a. High Impact	Eval Rating
(for NQF staff use) Specific NPP goal:	
1a.1 Demonstrated High Impact Aspect of Healthcare: Affects large numbers, Leading cause of morbidity/mortality, High resource use, Severity of illness, Patient/societal consequences of poor quality 1a.2 1a.3 Summary of Evidence of High Impact: Hypertension is a high impact topic area: •One in three adults in the United States has high blood pressure. •Approximately 69% of those who have a first heart attack, 77% who have a first stroke, and 74% of those with congestive heart failure have a blood pressure greater than 140/90 mmHg (based on unpublished estimates from the National Heart, Lung, & Blood Institute [NHLBI]) •Hypertension is associated with shorter overall life expectancy, shorter life expectancy free from cardiovascular disease, and more years lived with cardiovascular disease (based on data from the Framingham Heart Study [FHS]/NHLBI). •From 1995-2005 the death rate from high blood pressure increased 25.2%. •In 2006, the number of ambulatory care visits for hypertension was 44,879,000. •The 2009 estimated direct and indirect costs of hypertension are \$73.4 billion. 1a.4 Citations for Evidence of High Impact: Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics - 2009 update: a report from the american heart association statistics committee and stroke statistics subcommittee. Circulation. 2009;199(3):21-181.	1a C <input type="checkbox"/> P <input type="checkbox"/> M <input type="checkbox"/> N <input type="checkbox"/>
1b. Opportunity for Improvement	1b

Comment [KP1]: 1a. The measure focus addresses:
 •a specific national health goal/priority identified by NQF's National Priorities Partners; OR
 •a demonstrated high impact aspect of healthcare (e.g., affects large numbers, leading cause of morbidity/mortality, high resource use (current and/or future), severity of illness, and patient/societal consequences of poor quality).

Comment [KP2]: 1b. Demonstration of quality problems and opportunity for improvement, i.e., data demonstrating considerable variation, or overall poor performance, in the quality of care across providers and/or population groups (disparities in care).

<p>1b.1 Benefits (improvements in quality) envisioned by use of this measure: This measure aims to improve the number of patients whose blood pressure is under control and encourage appropriate management in cases where it is not.</p> <p>1b.2 Summary of data demonstrating performance gap (variation or overall poor performance) across providers: From 1998-2000, •Approximately 76% of hypertensive patients with a consistent average SBP >140 or DBP >90 over 6 months had either a change in dose in their antihypertensive regimen or repeated education regarding lifestyle modifications (1)</p> <p>Performance relating to the National Committee for Quality Assurance measure of controlling high blood pressure shows the following for 2009 (2) Measure: Percentage of members 18 to 85 years of age who had a diagnosis of hypertension and whose blood pressure was adequately controlled to <140/90 mmHg during the measurement year. Both systolic and diastolic pressure must be at or under this threshold for blood pressure to be considered controlled. 63.4 (commercial); 58.5 (Medicare); 55.8 (Medicaid)</p> <p>Using data from the National Ambulatory Medical Survey (NAMS), Ma and Stafford found that 39% of treated visits for hypertension were at recommended blood pressure goals. Additionally: •There was geographic variability in the odds of being treated for hypertension (South vs. Northeast - 2.6) and by visit type (first time vs. return visits - 1.6). •Odds of blood pressure control were greater for patients with comorbidities (1.6).(3)</p> <p>(1)Technical Appendix to McGlynn EA, Asch SM, Adams JL, et al. Who is at greatest risk for receiving poor quality health care? New England Journal of Medicine. 2006;354:1147-1156. Available at: www.rand.org/pubs/working_papers/WR-174-1. (2)The State of Healthcare Quality 2009. National Committee for Quality Assurance. Washington DC. Available at: http://www.ncqa.org/Portals/0/Newsroom/SOHC/SOHC_2009.pdf. (3)Ma J, Stafford RS. Screening, treatment, and control of hypertension in US private physician offices, 2003-2004. Hypertension. 2008;51:1275-1281.</p> <p>1b.3 Citations for data on performance gap:</p> <p>1b.4 Summary of Data on disparities by population group: We are not aware of any publications/evidence outlining disparities in this area.</p> <p>1b.5 Citations for data on Disparities:</p>	<p>C <input type="checkbox"/></p> <p>P <input type="checkbox"/></p> <p>M <input type="checkbox"/></p> <p>N <input type="checkbox"/></p>
<p>1c. Outcome or Evidence to Support Measure Focus</p> <p>1c.1 Relationship to Outcomes (For non-outcome measures, briefly describe the relationship to desired outcome. For outcomes, describe why it is relevant to the target population): Effective management of blood pressure in patients with hypertension can help prevent cardiovascular events, including myocardial infarction, stroke, and the development of heart failure.(1)</p> <p>(1)National Institutes of Health, National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program. The seventh report of the Joint National Committee on Prevention, Detection, and Treatment of High Blood Pressure. NIH Publication No. 04-5230. September 2004.</p> <p>1c.2-3. Type of Evidence: Evidence-based guideline</p> <p>1c.4 Summary of Evidence (as described in the criteria; for outcomes, summarize any evidence that healthcare services/care processes influence the outcome): Blood pressure control is recommended. Treating SBP and DBP to targets that are <140/90 mm Hg is associated with a decrease in CVD risk complications. In patients with hypertension and diabetes or renal</p>	<p>1c</p> <p>C <input type="checkbox"/></p> <p>P <input type="checkbox"/></p> <p>M <input type="checkbox"/></p> <p>N <input type="checkbox"/></p>

Comment [k3]: 1 Examples of data on opportunity for improvement include, but are not limited to: prior studies, epidemiologic data, measure data from pilot testing or implementation. If data are not available, the measure focus is systematically assessed (e.g., expert panel rating) and judged to be a quality problem.

Comment [k4]: 1c. The measure focus is:
 •an outcome (e.g., morbidity, mortality, function, health-related quality of life) that is relevant to, or associated with, a national health goal/priority, the condition, population, and/or care being addressed;
 OR
 •if an intermediate outcome, process, structure, etc., there is evidence that supports the specific measure focus as follows:
 oIntermediate outcome - evidence that the measured intermediate outcome (e.g., blood pressure, Hba1c) leads to improved health/avoidance of harm or cost/benefit.
 oProcess - evidence that the measured clinical or administrative process leads to improved health/avoidance of harm and if the measure focus is on one step in a multi-step care process, it measures the step that has the greatest effect on improving the specified desired outcome(s).
 oStructure - evidence that the measured structure supports the consistent delivery of effective processes or access that lead to improved health/avoidance of harm or cost/benefit.
 oPatient experience - evidence that an association exists between the measure of patient experience of health care and the outcomes, values and preferences of individuals/ the public.
 oAccess - evidence that an association exists between access to a health service and the outcomes of, or experience with, care.
 oEfficiency - demonstration of an association between the measured resource use and level of performance with respect to one or more of the other five IOM aims of quality.

Comment [k5]: 4 Clinical care processes typically include multiple steps: assess → identify problem/potential problem → choose/plan intervention (with patient input) → provide intervention → evaluate impact on health status. If the measure focus is one step in such a multi-step process, the step with the greatest effect on the desired outcome should be selected as the focus of measurement. For example, although assessment of immunization status and recommending immunization are necessary steps, they are not sufficient to achieve the desired impact on health status - patients must be vaccinated to achieve immunity. This does not preclude consideration of measures of preventive screening interventions where there is a strong link with desired outcomes (e.g., mammography) or measures for multiple care processes that affect a single outcome.

disease, the BP goal is <130/80 mm Hg.

1c.5 Rating of strength/quality of evidence (also provide narrative description of the rating and by whom):

Strength/Quality of Evidence not Rated

1c.6 Method for rating evidence:

1c.7 Summary of Controversy/Contradictory Evidence:

1c.8 Citations for Evidence (other than guidelines):

1c.9 Quote the Specific guideline recommendation (including guideline number and/or page number):

Treating SBP and DBP to targets that are <140/90 mm Hg is associated with a decrease in CVD risk complications. In patients with hypertension and diabetes or renal disease, the BP goal is <130/80 mm Hg. (JNC VII, 2004)

Therapy begins with lifestyle modification, and if BP goal is not achieved, thiazide-type diuretics should be used as initial therapy for most patients, either alone or in combination with one of the other classes (ACEIs, ARBs, BBs, or CCBs) that have also been shown to reduce one or more hypertensive complications in randomized-controlled outcome trials. Selection of one of these other agents as initial therapy is recommended when a diuretic cannot be used or a competing indication is present that requires use of a specific drug...If the initial drug selected is not tolerated or contraindicated, then a drug from one of the other classes proven to reduce cardiovascular events should be substituted. (JNC VIII, 2004)

Compelling indications for use of individual drug classes for treatment of hypertension (JNC VIII, 2004):

Stable angina and silent ischemia

Unless contraindicated, pharmacologic therapy should be initiated with a BB. BBs will lower BP; reduce symptoms of angina; improve mortality; and reduce cardiac output, heart rate, and AV conduction. The reduced inotropy and heart rate decrease myocardial oxygen demand.

If angina and BP are not controlled by BB therapy alone, or if BBs are contraindicated, as in the presence of severe reactive airway disease, severe peripheral arterial disease, high-degree AV block, or the sick sinus syndrome, either long-acting dihydropyridine or nondihydropyridine CCBs may be used. CCBs decrease total peripheral resistance, which leads to reduction in BP and wall tension. CCBs also decrease coronary resistance and enhance post-stenotic coronary perfusion. Nondihydropyridine CCBs can decrease heart rate; when in combination with a BB however, they may cause severe bradycardia or high degrees of heart block. Therefore, long-acting dihydropyridine CCBs are preferred for combination therapy with BBs. If angina or BP is still not controlled with this two-drug regimen, nitrates can be added, but these should be used with caution in patients taking phosphodiesterase-5 inhibitors such as sildenafil. Short-acting dihydropyridine CCBs should not be used because of their potential to increase mortality, especially in the setting of acute MI.

Heart Failure

HF is a "compelling indication" for the use of ACEI. Abundant evidence exists to justify their use with all stages of HF. In patients intolerant of ACEIs, ARBs may be used. BBs are also recommended for HF because of clinical studies demonstrating decreased morbidity and mortality, and improvement in HF symptoms.

Diabetes

Thiazide-type diuretics are beneficial in diabetics, either alone or as part of a combined regimen.

Therapy with an ACEI also is an important component of most regimens to control BP in diabetic patients. ACEIs may be used alone for BP lowering but are much more effective when combined with a thiazide -type diuretic or other antihypertensive drugs.

BBs, especially beta 1-selective agents, are beneficial to diabetics as part of multidrug therapy, but their value as monotherapy is less clear. A BB is indicated in a diabetic with IHD but may be less effective in preventing stroke than an ARB as was found in the LIFE study. Although BBs can cause adverse effects on glucose homeostasis in diabetics, including worsening of insulin sensitivity and potential masking of the

Comment [k6]: 3 The strength of the body of evidence for the specific measure focus should be systematically assessed and rated (e.g., USPSTF grading system <http://www.ahrq.gov/clinic/uspstf07/methods/benefit.htm>). If the USPSTF grading system was not used, the grading system is explained including how it relates to the USPSTF grades or why it does not. However, evidence is not limited to quantitative studies and the best type of evidence depends upon the question being studied (e.g., randomized controlled trials appropriate for studying drug efficacy are not well suited for complex system changes). When qualitative studies are used, appropriate qualitative research criteria are used to judge the strength of the evidence.

<p>epinephrine-mediated symptoms of hypoglycemia, these problems are usually easily managed and are not absolute contraindication for BB use.</p> <p>CCBs may be useful to diabetics, particularly as part of combination therapy to control BP.</p> <p>Chronic Kidney Disease The joint recommendation of the American Society of Nephrology and the National Kidney Foundation provide useful guidelines for the management of hypertensive patients with CKD. They recommend a goal BP for all CKD patients of <130/80 mm Hg and the need for more than one antihypertensive drug to achieve this goal. The guidelines indicate that most patients with CKD should receive an ACEI or ARB in combination with a diuretic, and many will require a loop diuretic rather than a thiazide. In addition, if there is a conflict between the goals of slowing progression of CKD and CV risk reduction, individual decision making is recommended based on risk stratification.</p> <p>1c.10 Clinical Practice Guideline Citation: National Institutes of Health, National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program. The seventh report of the Joint National Committee on Prevention, Detection, and Treatment of High Blood Pressure. NIH Publication No. 04-5230. September 2004.</p> <p>1c.11 National Guideline Clearinghouse or other URL: http://www.nhlbi.nih.gov/guidelines/hypertension/</p> <p>1c.12 Rating of strength of recommendation (also provide narrative description of the rating and by whom): Strength of Recommendation not Rated</p> <p>1c.13 Method for rating strength of recommendation (If different from USPSTF system, also describe rating and how it relates to USPSTF):</p> <p>1c.14 Rationale for using this guideline over others: It is the PCPI policy to use guidelines, which are evidence-based, applicable to physicians and other healthcare providers, and developed by a national specialty organization or government agency. In addition, the PCPI has now expanded what is acceptable as the evidence base for measures to included documented quality improvement (QI) initiatives or implementation projects that have demonstrated improvement in the quality of care.</p>	
<p>TAP/Workgroup: What are the strengths and weaknesses in relation to the subcriteria for <i>Importance to Measure and Report</i>?</p>	1
<p>Steering Committee: Was the threshold criterion, <i>Importance to Measure and Report</i>, met? Rationale:</p>	1 Y <input type="checkbox"/> N <input type="checkbox"/>
2. SCIENTIFIC ACCEPTABILITY OF MEASURE PROPERTIES	
<p>Extent to which the measure, <u>as specified</u>, produces consistent (reliable) and credible (valid) results about the quality of care when implemented. (evaluation criteria)</p>	Eval Rating
2a. MEASURE SPECIFICATIONS	
<p>S.1 Do you have a web page where current detailed measure specifications can be obtained? S.2 If yes, provide web page URL:</p>	
<p>2a. Precisely Specified</p>	
<p>2a.1 Numerator Statement (Brief, text description of the numerator - what is being measured about the target population, e.g. target condition, event, or outcome): Patients with a blood pressure <140/90 mm Hg</p> <p>OR</p>	2a- specs C <input type="checkbox"/> P <input type="checkbox"/> M <input type="checkbox"/> N <input type="checkbox"/>

Comment [k7]: USPSTF grading system <http://www.ahrq.gov/clinic/uspstf/grades.htm>: A - The USPSTF recommends the service. There is high certainty that the net benefit is substantial. B - The USPSTF recommends the service. There is high certainty that the net benefit is moderate or there is moderate certainty that the net benefit is moderate to substantial. C - The USPSTF recommends against routinely providing the service. There may be considerations that support providing the service in an individual patient. There is at least moderate certainty that the net benefit is small. Offer or provide this service only if other considerations support the offering or providing the service in an individual patient. D - The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits. I - The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined.

Comment [KP8]: 2a. The measure is well defined and precisely specified so that it can be implemented consistently within and across organizations and allow for comparability. The required data elements are of high quality as defined by NQF's Health Information Technology Expert Panel (HITEP).

Patients with a blood pressure \geq 140/90 mm Hg and prescribed 2 or more anti-hypertensive medications during the most recent office visit within a 12-month period

Instructions:

Report number of patients for 1st numerator component (outcome)

AND

Report number of patients for 2nd numerator component (process)

AND

Report total number of patients for all numerator components

2a.2 Numerator Time Window (*The time period in which cases are eligible for inclusion in the numerator*): once during the 12-month measurement period

2a.3 Numerator Details (*All information required to collect/calculate the numerator, including all codes, logic, and definitions*):

BP value used for measure calculation:

- Must be specified in medical record if >1 value (systolic/diastolic) recorded, and
- Must be value upon which treatment decision was based, and
- May be obtained by measurement during office visit, review of home blood pressure log, OR review of 24 hour ambulatory blood pressure monitor

Prescribed may include prescriptions given to the patient for 2 or more anti-hypertensive medications at most recent office visit OR patient already taking 2 or more anti-hypertensive medications as documented in the current medication list (Each anti-hypertensive component in a combination medication should be counted individually)

See attached for EHR specifications.

For Claims/Administrative: Patients with a blood pressure $<140/90$ mm Hg

- 3074F Most recent systolic blood pressure, <130 mm Hg

OR

- 3075F Most recent systolic blood pressure, 130 to 139 mm Hg

AND

- 3078F Most recent diastolic blood pressure, <80 mm Hg

OR

- 3079F Most recent diastolic blood pressure, 80 - 89 mm Hg

OR

Patients with a blood pressure \geq 140/90 mm Hg and prescribed 2 or more anti-hypertensive medications during the most recent office visit within a 12 month period

- 3077F Most recent systolic blood pressure \geq 140 mm Hg

AND

- 3080F Most recent diastolic blood pressure \geq 90 mm Hg

AND

- CPT Category II (in development) 4XXXF- Two or more anti-hypertensive medications prescribed

2a.4 Denominator Statement (*Brief, text description of the denominator - target population being measured*):

All visits for patients aged 18 years and older with a diagnosis of hypertension

2a.5 Target population gender: Female, Male

2a.6 Target population age range: Aged 18 years and older

2a.7 Denominator Time Window (*The time period in which cases are eligible for inclusion in the denominator*):

12 consecutive months

2a.8 Denominator Details (*All information required to collect/calculate the denominator - the target population being measured - including all codes, logic, and definitions*):

See attached for EHR Specifications.

For Claims/Administrative: see coding tables attached for coding: (ICD-9-CM, ICD-10-CM, SNOMED, CPT)
<p>2a.9 Denominator Exclusions (<i>Brief text description of exclusions from the target population</i>): Documentation of medical reason(s) for not prescribing 2 or more anti-hypertensive medications (eg, allergy, intolerant, postural hypotension)</p> <p>Documentation of patient reason(s) for not prescribing 2 or more anti-hypertensive medications (eg, patient declined)</p> <p>Documentation of system reason(s) for not prescribing 2 or more anti-hypertensive medications (eg, financial reasons)</p>
<p>2a.10 Denominator Exclusion Details (<i>All information required to collect exclusions to the denominator, including all codes, logic, and definitions</i>):</p> <ul style="list-style-type: none"> - Append modifier to CPT II code (in development) 4XXX-1P - Append modifier to CPT II code (in development) 4XXX-2P - Append modifier to CPT II code (in development) 4XXX-3P
<p>2a.11 Stratification Details/Variables (<i>All information required to stratify the measure including the stratification variables, all codes, logic, and definitions</i>):</p>
<p>2a.12-13 Risk Adjustment Type: No risk adjustment necessary</p>
<p>2a.14 Risk Adjustment Methodology/Variables (<i>List risk adjustment variables and describe conceptual models, statistical models, or other aspects of model or method</i>):</p>
<p>2a.15-17 Detailed risk model available Web page URL or attachment:</p>
<p>2a.18-19 Type of Score: Rate/proportion</p> <p>2a.20 Interpretation of Score: Better quality = Higher score</p>
<p>2a.21 Calculation Algorithm (<i>Describe the calculation of the measure as a flowchart or series of steps</i>): See attached for calculation algorithm</p>
<p>2a.22 Describe the method for discriminating performance (<i>e.g., significance testing</i>):</p>
<p>2a.23 Sampling (Survey) Methodology (<i>If measure is based on a sample (or survey), provide instructions for obtaining the sample, conducting the survey and guidance on minimum sample size (response rate)</i>):</p>
<p>2a.24 Data Source (<i>Check the source(s) for which the measure is specified and tested</i>) Paper medical record/flow-sheet, Electronic administrative data/claims, Electronic clinical data, Electronic Health/Medical Record, Registry data</p>
<p>2a.25 Data source/data collection instrument (<i>Identify the specific data source/data collection instrument, e.g. name of database, clinical registry, collection instrument, etc.</i>): This measure, in its previous specifications, is currently being used in the ACCF PINNACLE registry for the outpatient office setting.</p>
<p>2a.26-28 Data source/data collection instrument reference web page URL or attachment: URL www.pinnacleregistry.org</p>
<p>2a.29-31 Data dictionary/code table web page URL or attachment:</p>
<p>2a.32-35 Level of Measurement/Analysis (<i>Check the level(s) for which the measure is specified and tested</i>) Clinicians: Individual, Clinicians: Group</p>
<p>2a.36-37 Care Settings (<i>Check the setting(s) for which the measure is specified and tested</i>) Home, Ambulatory Care: Office, Ambulatory Care: Clinic, Nursing home (NH) /Skilled Nursing Facility (SNF),</p>

Comment [k9]: 11 Risk factors that influence outcomes should not be specified as exclusions.
 12 Patient preference is not a clinical exception to eligibility and can be influenced by provider interventions.

<p>Ambulatory Care: Hospital Outpatient, Assisted Living, Group homes</p> <p>2a.38-41 Clinical Services (<i>Healthcare services being measured, check all that apply</i>) Clinicians: PA/NP/Advanced Practice Nurse, Clinicians: Physicians (MD/DO)</p>		
TESTING/ANALYSIS		
2b. Reliability testing		
<p>2b.1 Data/sample (<i>description of data/sample and size</i>): PCPI staff analysis of available testing data for this measure is ongoing and will be submitted to NQF separately and at the earliest possible date.</p> <p>2b.2 Analytic Method (<i>type of reliability & rationale, method for testing</i>):</p> <p>2b.3 Testing Results (<i>reliability statistics, assessment of adequacy in the context of norms for the test conducted</i>):</p>		2b C <input type="checkbox"/> P <input type="checkbox"/> M <input type="checkbox"/> N <input type="checkbox"/>
2c. Validity testing		
<p>2c.1 Data/sample (<i>description of data/sample and size</i>):</p> <p>2c.2 Analytic Method (<i>type of validity & rationale, method for testing</i>): All PCPI performance measures are assessed for content validity by expert work group members during the development process. Additional input on the content validity of draft measures is obtained through a 30-day public comment period and by also soliciting comments from a panel of consumer, purchaser, and patient representatives convened by the PCPI specifically for this purpose. All comments received are reviewed by the expert work group and the measures adjusted as needed. Other external review groups (eg, focus groups) may be convened if there are any remaining concerns related to the content validity of the measures.</p> <p>2c.3 Testing Results (<i>statistical results, assessment of adequacy in the context of norms for the test conducted</i>):</p>		2c C <input type="checkbox"/> P <input type="checkbox"/> M <input type="checkbox"/> N <input type="checkbox"/>
2d. Exclusions Justified		
<p>2d.1 Summary of Evidence supporting exclusion(s): The Hypertension Work Group agreed to include a medical reason exception so that clinicians can exclude patients for whom the prescription of two or more antihypertensive medications may not be indicated or contraindicated (eg, allergy, intolerant, postural hypotension). A patient reason exception has been included for patients who might decline this particular pharmacologic treatment. Additionally, a system reason exception has been included to account for potential financial constraints that would inhibit use/prescription of two or more antihypertensive medications.</p> <p>2d.2 Citations for Evidence:</p> <p>2d.3 Data/sample (<i>description of data/sample and size</i>):</p> <p>2d.4 Analytic Method (<i>type analysis & rationale</i>):</p> <p>2d.5 Testing Results (<i>e.g., frequency, variability, sensitivity analyses</i>):</p>		2d C <input type="checkbox"/> P <input type="checkbox"/> M <input type="checkbox"/> N <input type="checkbox"/> NA <input type="checkbox"/>
2e. Risk Adjustment for Outcomes/ Resource Use Measures		
<p>2e.1 Data/sample (<i>description of data/sample and size</i>):</p>		2e C <input type="checkbox"/> P <input type="checkbox"/>

Comment [KP10]: 2b. Reliability testing demonstrates the measure results are repeatable, producing the same results a high proportion of the time when assessed in the same population in the same time period.

Comment [k11]: 8 Examples of reliability testing include, but are not limited to: inter-rater/abstractor or intra-rater/abstractor studies; internal consistency for multi-item scales; test-retest for survey items. Reliability testing may address the data items or final measure score.

Comment [KP12]: 2c. Validity testing demonstrates that the measure reflects the quality of care provided, adequately distinguishing good and poor quality. If face validity is the only validity addressed, it is systematically assessed.

Comment [k13]: 9 Examples of validity testing include, but are not limited to: determining if measure scores adequately distinguish between providers known to have good or poor quality assessed by another valid method; correlation of measure scores with another valid indicator of quality for the specific topic; ability of measure scores to predict scores on some other related valid measure; content validity for multi-item scales/tests. Face validity is a subjective assessment by experts of whether the measure reflects the quality of care (e.g., whether the proportion of patients with BP < 140/90 is a marker of quality). If face validity is the only validity addressed, it is systematically assessed (e.g., ratings by relevant stakeholders) and the measure is judged to represent quality care for the specific topic and that the measure focus is the most important aspect of quality for the specific topic.

Comment [KP14]: 2d. Clinically necessary measure exclusions are identified and must be:
 •supported by evidence of sufficient frequency of occurrence so that results are distorted without the exclusion;
 AND
 •a clinically appropriate exception (e.g., contraindication) to eligibility for the measure focus;
 AND
 •precisely defined and specified:
 –if there is substantial variability in exclusions across providers, the measure is specified so that exclusions are computable and the effect on the measure is transparent (i.e., impact clearly delineated, such as number of ca... [1])

Comment [k15]: 10 Examples of evidence that an exclusion distorts measure results include, but are not limited to: frequency of occurrence, sensitivity analyses with and without the exclusion, and variability of exclusions across providers.

Comment [KP16]: 2e. For outcome measures and other measures (e.g., resource use) when indicated:
 •an evidence-based risk-adjustment strategy (e.g., risk models, risk stratification) is specified and is based on patient clinical factors that influence the measured outcome (but not disparities in care) and are present at start of care; Error! Bookmark not defined. OR ... [2]

<p>2e.2 Analytic Method (<i>type of risk adjustment, analysis, & rationale</i>): This is a process measure; risk adjustment is not indicated.</p> <p>2e.3 Testing Results (<i>risk model performance metrics</i>):</p> <p>2e.4 If outcome or resource use measure is not risk adjusted, provide rationale:</p>	M <input type="checkbox"/> N <input type="checkbox"/> NA <input type="checkbox"/>
<p>2f. Identification of Meaningful Differences in Performance</p> <p>2f.1 Data/sample from Testing or Current Use (<i>description of data/sample and size</i>):</p> <p>2f.2 Methods to identify statistically significant and practically/meaningfully differences in performance (<i>type of analysis & rationale</i>):</p> <p>2f.3 Provide Measure Scores from Testing or Current Use (<i>description of scores, e.g., distribution by quartile, mean, median, SD, etc.; identification of statistically significant and meaningfully differences in performance</i>):</p>	2f C <input type="checkbox"/> P <input type="checkbox"/> M <input type="checkbox"/> N <input type="checkbox"/>
<p>2g. Comparability of Multiple Data Sources/Methods</p> <p>2g.1 Data/sample (<i>description of data/sample and size</i>):</p> <p>2g.2 Analytic Method (<i>type of analysis & rationale</i>):</p> <p>2g.3 Testing Results (<i>e.g., correlation statistics, comparison of rankings</i>):</p>	2g C <input type="checkbox"/> P <input type="checkbox"/> M <input type="checkbox"/> N <input type="checkbox"/> NA <input type="checkbox"/>
<p>2h. Disparities in Care</p> <p>2h.1 If measure is stratified, provide stratified results (<i>scores by stratified categories/cohorts</i>): The measure is not stratified by patient groups or cohorts that could potentially be affected by disparities in care, nor are we aware of any existing research identifying disparities in care that may be relevant to this measure.</p> <p>2h.2 If disparities have been reported/identified, but measure is not specified to detect disparities, provide follow-up plans: We are not aware of any relevant disparities that have been identified.</p>	2h C <input type="checkbox"/> P <input type="checkbox"/> M <input type="checkbox"/> N <input type="checkbox"/> NA <input type="checkbox"/>
<p>TAP/Workgroup: What are the strengths and weaknesses in relation to the subcriteria for <i>Scientific Acceptability of Measure Properties</i>?</p>	2
<p>Steering Committee: Overall, to what extent was the criterion, <i>Scientific Acceptability of Measure Properties</i>, met? Rationale:</p>	2 C <input type="checkbox"/> P <input type="checkbox"/> M <input type="checkbox"/> N <input type="checkbox"/>
3. USABILITY	
<p>Extent to which intended audiences (e.g., consumers, purchasers, providers, policy makers) can understand the results of the measure and are likely to find them useful for decision making. (evaluation criteria)</p>	Eval Rating
<p>3a. Meaningful, Understandable, and Useful Information</p> <p>3a.1 Current Use: In use</p> <p>3a.2 Use in a public reporting initiative (disclosure of performance results to the public at large) (<i>If used in a public reporting initiative, provide name of initiative(s), locations, Web page URL(s). If not publicly</i></p>	3a C <input type="checkbox"/> P <input type="checkbox"/> M <input type="checkbox"/> N <input type="checkbox"/>

Comment [k17]: 13 Risk models should not obscure disparities in care for populations by including factors that are associated with differences/inequalities in care such as race, socioeconomic status, gender (e.g., poorer treatment outcomes of African American men with prostate cancer, inequalities in treatment for CVD risk factors between men and women). It is preferable to stratify measures by race and socioeconomic status rather than adjusting out differences.

Comment [KP18]: 2f. Data analysis demonstrates that methods for scoring and analysis of the specified measure allow for identification of statistically significant and practically/clinically meaningful differences in performance.

Comment [k19]: 14 With large enough sample sizes, small differences that are statistically significant may or may not be practically or clinically meaningful. The substantive question may be, for example, whether a statistically significant difference of one percentage point in the percentage of patients who received smoking cessation counseling (e.g., 74% v. 75%) is clinically meaningful; or whether a statistically significant difference of \$25 in cost for an episode of care (e.g., \$5,000 v. \$5,025) is practically meaningful. Measures with overall poor performance may not demonstrate much variability across providers.

Comment [KP20]: 2g. If multiple data sources/methods are allowed, there is demonstration they produce comparable results.

Comment [KP21]: 2h. If disparities in care have been identified, measure specifications, scoring, and analysis allow for identification of disparities through stratification of results (e.g., by race, ethnicity, socioeconomic status, gender); OR rationale/data justifies why stratification is not necessary or not feasible.

Comment [KP22]: 3a. Demonstration that information produced by the measure is meaningful, understandable, and useful to the intended audience(s) for both public reporting (e.g., focus group, cognitive testing) and informing quality improvement (e.g., quality improvement initiatives). An important outcome that may not have an identified improvement strategy still can be useful for informing quality improvement by identifying the need for and stimulating new approaches to improvement.

reported, state the plans to achieve public reporting within 3 years):

This measure is not yet used in any public reporting initiative. The measure will, however, be eligible for inclusion in the CMS PQRS and other government programs in 2012 and would thus provide information about clinician participation to the public. The ACCF, AHA, and PCPI believe that the reporting of such participation information is a beneficial first step on a trajectory toward the public reporting of performance results, which is most appropriate after the measures are thoroughly tested and the reliability of the performance data has been validated. Continued NQF endorsement will facilitate our ongoing progress toward this public reporting objective.

3a.3 If used in other programs/initiatives (If used in quality improvement or other programs/initiatives, name of initiative(s), locations, Web page URL(s). If not used for QI, state the plans to achieve use for QI within 3 years):

All PCPI measures are suitable for use in quality improvement initiatives and are made freely available on the PCPI website and through the implementation efforts of medical specialty societies and other PCPI members. The PCPI strongly encourages the use of its measures in QI initiatives and seeks to provide information on such initiatives to PCPI members.

The American Heart Association's Get With The Guidelines®-Outpatient (GWTG-O) is a virtual performance improvement program that will improve adherence to evidence-based care in the outpatient setting, including specialist practices, general healthcare practices and health clinics. GWTG-Outpatient historically has had a long history of quality improvement for cardiovascular care. They have published 65 publications over the past 10 years. This program is designed to assist healthcare professionals in the outpatient setting to provide the best possible care to patients. This program collects a number of clinical measures for primary and secondary prevention. Clinical measure sets include those developed by American Heart Association, including those co-developed with other organizations, such as the American College of Cardiology Foundation and the American Medical Association, as well as other National Quality Forum endorsed measures.

Through this program, we collect data on clinical measures affecting a number of cardiovascular related conditions including, atrial fibrillation, coronary artery disease, heart failure, hypertension, diabetes, and preventative care. The primary analytical system used is Duke Clinical Research Institute. Get With The Guidelines®-Outpatient is a quality improvement program that can be utilized for Maintenance of Certification (MOC) with groups like American Board of Internal Medicine (ABIM) and American Board of Family Medicine (ABFM). ABIM has confirmed that the reports received from Get With The Guidelines-Outpatient can be utilized in completion of their Self-Directed Practice Improvement Module (PIM). The Self-Directed PIM provides one pathway for earning practice performance credit in ABIM's MOC program. This program includes several integral components: A preliminary Continuing Education (CE) course for the care team, data submission and reporting that is integrated with existing Electronic Health Records (EHRs)/health technology platforms, corresponding professional and provider education including webinars, online tools and resources, digital access to reference materials and videos through the Get With The Guidelines®-Outpatient website (<http://outpatient.heart.org>). The free continuing education activity titled, Outpatient Quality Improvement Focus, addresses the quality chasm and treatment gap, presents the benefits of quality improvement and identifies the steps necessary for implementation in the practice setting. This continuing education activity is certified for physicians, nurses and pharmacists.

The American College of Cardiology Foundation's Cardiology Practice Improvement Pathway (CPIP) uses clinical measure sets that are developed and specified by the American College of Cardiology Foundation with the American Heart Association and the American Medical Association's Physician Consortium for Performance Improvement for Hypertension, Stable Coronary Artery Disease, Heart Failure, and Atrial Fibrillation/Atrial Flutter. This program is intended as an approved quality improvement product that can be applied toward ABIM's Part IV practice performance requirement for Maintenance of Certification (ABIM AQI application submitted). They are in the process of creating a homepage on the Cardiosource.org homepage. The URL will be cardiosource.org/cpip. The web-based tool will be available after spring 2011. Through an online webinar hosted in November 2010, CPIP anticipates enrolling 50 - 100 practices during 2011 which will provide data from about 500-1,000 cardiologists. This ACCF initiative has contracted with the NY QIO: IPRO to analyze and scores based on thresholds. Of the 100 points needed to achieve recognition in the program, 70 come directly from clinical points such as the Heart Failure measures that are being submitted to NQF for consideration. IPRO will audit 5% of practices who submit their data for

recognition evaluation.	
<p>The American College of Cardiology Foundation's has an Performance Improvement program entitled "A New Era" which is an educational format approved for credit by the American Medical Association (AMA) and the American Nursing Credentialing Center. This continuing medical education program blends both quality improvement and educational methodologies to provide a high quality learning experience that impacts changes to practice. These activities are structured, long-term processes in which a healthcare professional learns about the heart failure specific performance metrics, uses metrics to retrospectively assess his practice, applies these metrics prospectively over a useful interval, and reevaluates his performance. As part of this process, clinicians set goals for change and engage in structured learning activities to improve their performance. As of December 6th, 2010:</p> <ul style="list-style-type: none"> - 425 clinicians have enrolled in A New ERA - The data is generated from all but four states (Montana, New Hampshire, South Dakota, and Wyoming) - 82% are physicians - 90% agreed or strongly agreed that performance metric data were valuable - 80% agreed or strongly agreed that performance metric data review would help them improve their practice - No one has finished the program, as it takes several months to do so <p>In 2008, the American College of Cardiology Foundation launched the PINNACLE program (formerly known as the Improving Continuous Cardiac Care or IC3). This was the first, national, prospective, outpatient based cardiac QI registry in the US. While participation is voluntary, this registry collects a variety of longitudinal patient data at the point of service, including patients' symptoms, vital signs, medication, and recent hospitalizations. Jointly developed ACCF/AHA/PCPI measures for Coronary Artery Disease, Heart Failure, and Atrial Fibrillation. Data collection is achieved in 2 ways for the practices: paper forms or practice's electronic medical record data collection systems. The primary analytical system used is St. Luke's Mid America Heart Institute. The ACCF registry, PINNACLE, pulls data from outpatient facilities via paper flowsheets or 14 EHR vendors. As of December 10, 2010, there are 47 practices collecting data at 200 sites with 276,000 unique patients representing 1 million documented encounters.</p> <p>Testing of Interpretability (<i>Testing that demonstrates the results are understood by the potential users for public reporting and quality improvement</i>)</p> <p>3a.4 Data/sample (<i>description of data/sample and size</i>):</p> <p>3a.5 Methods (<i>e.g., focus group, survey, QI project</i>):</p> <p>3a.6 Results (<i>qualitative and/or quantitative results and conclusions</i>):</p>	
3b/3c. Relation to other NQF-endorsed measures	
3b.1 NQF # and Title of similar or related measures:	
(for NQF staff use) Notes on similar/related endorsed or submitted measures:	
<p>3b. Harmonization</p> <p>If this measure is related to measure(s) already endorsed by NQF (e.g., same topic, but different target population/setting/data source <u>or</u> different topic but same target population):</p> <p>3b.2 Are the measure specifications harmonized? If not, why?</p>	<p>3b</p> <p>C <input type="checkbox"/></p> <p>P <input type="checkbox"/></p> <p>M <input type="checkbox"/></p> <p>N <input type="checkbox"/></p> <p>NA <input type="checkbox"/></p>
<p>3c. Distinctive or Additive Value</p> <p>3c.1 Describe the distinctive, improved, or additive value this measure provides to existing NQF-endorsed measures:</p> <p>5.1 If this measure is similar to measure(s) already endorsed by NQF (i.e., on the same topic and the</p>	<p>3c</p> <p>C <input type="checkbox"/></p> <p>P <input type="checkbox"/></p> <p>M <input type="checkbox"/></p> <p>N <input type="checkbox"/></p> <p>NA <input type="checkbox"/></p>

Comment [K23]: 3b. The measure specifications are harmonized with other measures, and are applicable to multiple levels and settings.

Comment [k24]: 16 Measure harmonization refers to the standardization of specifications for similar measures on the same topic (e.g., *influenza immunization* of patients in hospitals or nursing homes), or related measures for the same target population (e.g., eye exam and HbA1c for *patients with diabetes*), or definitions applicable to many measures (e.g., age designation for children) so that they are uniform or compatible, unless differences are dictated by the evidence. The dimensions of harmonization can include numerator, denominator, exclusions, and data source and collection instructions. The extent of harmonization depends on the relationship of the measures, the evidence for the specific measure focus, and differences in data sources.

Comment [KP25]: 3c. Review of existing endorsed measures and measure sets demonstrates that the measure provides a distinctive or additive value to existing NQF-endorsed measures (e.g., provides a more complete picture of quality for a particular condition or aspect of healthcare, is a more valid or efficient way to measure).

same target population), Describe why it is a more valid or efficient way to measure quality:	
TAP/Workgroup: What are the strengths and weaknesses in relation to the subcriteria for <i>Usability</i> ?	3
Steering Committee: Overall, to what extent was the criterion, <i>Usability</i> , met? Rationale:	3 C <input type="checkbox"/> P <input type="checkbox"/> M <input type="checkbox"/> N <input type="checkbox"/>
4. FEASIBILITY	
Extent to which the required data are readily available, retrievable without undue burden, and can be implemented for performance measurement. (evaluation criteria)	Eval Rating
4a. Data Generated as a Byproduct of Care Processes	
4a.1-2 How are the data elements that are needed to compute measure scores generated? Data generated as byproduct of care processes during care delivery (Data are generated and used by healthcare personnel during the provision of care, e.g., blood pressure, lab value, medical condition), Coding/abstraction performed by someone other than person obtaining original information (E.g., DRG, ICD-9 codes on claims, chart abstraction for quality measure or registry)	4a C <input type="checkbox"/> P <input type="checkbox"/> M <input type="checkbox"/> N <input type="checkbox"/>
4b. Electronic Sources	
4b.1 Are all the data elements available electronically? (<i>elements that are needed to compute measure scores are in defined, computer-readable fields, e.g., electronic health record, electronic claims</i>) Yes	4b C <input type="checkbox"/> P <input type="checkbox"/> M <input type="checkbox"/> N <input type="checkbox"/>
4b.2 If not, specify the near-term path to achieve electronic capture by most providers.	
4c. Exclusions	
4c.1 Do the specified exclusions require additional data sources beyond what is required for the numerator and denominator specifications? No	4c C <input type="checkbox"/> P <input type="checkbox"/> M <input type="checkbox"/> N <input type="checkbox"/> NA <input type="checkbox"/>
4c.2 If yes, provide justification.	
4d. Susceptibility to Inaccuracies, Errors, or Unintended Consequences	
4d.1 Identify susceptibility to inaccuracies, errors, or unintended consequences of the measure and describe how these potential problems could be audited. If audited, provide results. Although we are not currently aware of any unintended consequences related to this measure, we plan through an active redesign of the PCPI website to facilitate the collection of information on unintended consequences from the users of PCPI measures.	4d C <input type="checkbox"/> P <input type="checkbox"/> M <input type="checkbox"/> N <input type="checkbox"/>
4e. Data Collection Strategy/Implementation	
4e.1 Describe what you have learned/modified as a result of testing and/or operational use of the measure regarding data collection, availability of data/missing data, timing/frequency of data collection, patient confidentiality, time/cost of data collection, other feasibility/ implementation issues:	
4e.2 Costs to implement the measure (<i>costs of data collection, fees associated with proprietary measures</i>): Costs to implement the measure have not been calculated.	4e C <input type="checkbox"/> P <input type="checkbox"/> M <input type="checkbox"/> N <input type="checkbox"/>

Comment [KP26]: 4a. For clinical measures, required data elements are routinely generated concurrent with and as a byproduct of care processes during care delivery. (e.g., BP recorded in the electronic record, not abstracted from the record later by other personnel; patient self-assessment tools, e.g., depression scale; lab values, meds, etc.)

Comment [KP27]: 4b. The required data elements are available in electronic sources. If the required data are not in existing electronic sources, a credible, near-term path to electronic collection by most providers is specified and clinical data elements are specified for transition to the electronic health record.

Comment [KP28]: 4c. Exclusions should not require additional data sources beyond what is required for scoring the measure (e.g., numerator and denominator) unless justified as supporting measure validity.

Comment [KP29]: 4d. Susceptibility to inaccuracies, errors, or unintended consequences and the ability to audit the data items to detect such problems are identified.

Comment [KP30]: 4e. Demonstration that the data collection strategy (e.g., source, timing, frequency, sampling, patient confidentiality, etc.) can be implemented (e.g., already in operational use, or testing demonstrates that it is ready to put into operational use).

4e.3 Evidence for costs:	
4e.4 Business case documentation:	
TAP/Workgroup: What are the strengths and weaknesses in relation to the subcriteria for <i>Feasibility</i> ?	4
Steering Committee: Overall, to what extent was the criterion, <i>Feasibility</i> , met? Rationale:	4 C <input type="checkbox"/> P <input type="checkbox"/> M <input type="checkbox"/> N <input type="checkbox"/>
RECOMMENDATION	
(for NQF staff use) Check if measure is untested and only eligible for time-limited endorsement.	Time-limited <input type="checkbox"/>
Steering Committee: Do you recommend for endorsement? Comments:	Y <input type="checkbox"/> N <input type="checkbox"/> A <input type="checkbox"/>
CONTACT INFORMATION	
Co.1 Measure Steward (Intellectual Property Owner) Co.1 Organization American Medical Association, 515 N State St, Chicago, Illinois, 60654	
Co.2 Point of Contact Mark, Antman, DDS, MBA, mark.antman@ama-assn.org, 312-464-5056-	
Measure Developer If different from Measure Steward Co.3 Organization American Medical Association, 515 N State St, Chicago, Illinois, 60654	
Co.4 Point of Contact Mark, Antman, DDS, MBA, mark.antman@ama-assn.org, 312-464-5056-	
Co.5 Submitter If different from Measure Steward POC Mark, Antman, DDS, MBA, mark.antman@ama-assn.org, 312-464-5056-, American Medical Association	
Co.6 Additional organizations that sponsored/participated in measure development American College of Cardiology Foundation/American Heart Association	
ADDITIONAL INFORMATION	
Workgroup/Expert Panel involved in measure development Ad.1 Provide a list of sponsoring organizations and workgroup/panel members' names and organizations. Describe the members' role in measure development. Bruce Abramowitz, MD, FACC (interventional cardiology; measure implementation) Karen Alexander, MD (cardiology; geriatrics) Craig T. Beam, CRE (patient representative) Robert O. Bonow, MD, MACC, FAHA, FACP (cardiology) Jill S. Burkiewicz, PharmD, BCPS (pharmacy) Michael Crouch, MD, MSPH (family medicine) David C. Goff, Jr., MD, PhD, FAHA, FACP (internal medicine) Richard Hellman, MD, FACP, FACE (endocrinology) Thomas James, III, FACP, FAAP (health plan representative) Marjorie L. King, MD, FACC, FAACVPR (cardiology; cardiac rehabilitation) Edison A. Machado, Jr., MD, MBA (measure implementation) Eduardo Ortiz, MD, MPH (guideline development) Michael O'Toole, MD (cardiology; electrophysiology; measure implementation)	

<p>Stephen D. Persell, MD, MPH (internal medicine; measure implementation) Jesse M. Pines, MD, MBA, MSCE, FAAEM (emergency medicine) Frank J. Rybicki, MD, PhD (radiology) Lawrence B. Sadwin (patient representative) Joanna D. Sikkema, MSN, ANP-BC, FAHA (cardiology) Peter K. Smith, MD (thoracic surgery) Patrick J. Torcson, MD, FACP, MMM (hospital medicine) John B. Wong MD, FACP (internal medicine)</p> <p>PCPI measures are developed through cross-specialty, multi-disciplinary work groups. All medical specialties and other health care professional disciplines participating in patient care for the clinical condition or topic under study must be equal contributors to the measure development process. In addition, the PCPI strives to include on its work groups individuals representing the perspectives of patients, consumers, private health plans, and employers. This broad-based approach to measure development ensures buy-in on the measures from all stakeholders and minimizes bias toward any individual specialty or stakeholder group. All work groups have at least two co-chairs who have relevant clinical and/or measure development expertise and who are responsible for ensuring that consensus is achieved and that all perspectives are voiced.</p>
<p>Ad.2 If adapted, provide name of original measure: This measure is a combination of two previously developed PCPI measures - Hypertension: Blood Pressure Measurement and Hypertension: Plan of Care Ad.3-5 If adapted, provide original specifications URL or attachment</p>
<p>Measure Developer/Steward Updates and Ongoing Maintenance Ad.6 Year the measure was first released: 2003 Ad.7 Month and Year of most recent revision: 12, 2010 Ad.8 What is your frequency for review/update of this measure? Every 3 years or as new evidence becomes available that materially affects the measures. Ad.9 When is the next scheduled review/update for this measure? 12, 2013</p>
<p>Ad.10 Copyright statement/disclaimers: This Physician Performance Measurement Set (PPMS) and related data specifications were developed by the Physician Consortium for Performance Improvement® (the Consortium) including the American College of Cardiology (ACC), the American Heart Association (AHA) and the American Medical Association (AMA) to facilitate quality improvement activities by physicians. The performance measures contained in this PPMS are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications. While copyrighted, they can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the performance measures for commercial gain, or incorporation of the performance measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the PPMS require a license agreement between the user and the AMA, (on behalf of the Consortium) or the ACC or the AHA. Neither the AMA, ACC, AHA, the Consortium nor its members shall be responsible for any use of this PPMS.</p> <p>THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.</p> <p>© 2010 American College of Cardiology, American Heart Association and American Medical Association. All Rights Reserved.</p> <p>Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, the ACC, the AHA, the Consortium and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.</p>
<p>Ad.11 -13 Additional Information web page URL or attachment:</p>
<p>Date of Submission (MM/DD/YY): 12/14/2010</p>

2d. Clinically necessary measure exclusions are identified and must be:

- supported by evidence of sufficient frequency of occurrence so that results are distorted without the exclusion;
- AND

- a clinically appropriate exception (e.g., contraindication) to eligibility for the measure focus;

AND

- precisely defined and specified:

- if there is substantial variability in exclusions across providers, the measure is specified so that exclusions are computable and the effect on the measure is transparent (i.e., impact clearly delineated, such as number of cases excluded, exclusion rates by type of exclusion);

if patient preference (e.g., informed decision-making) is a basis for exclusion, there must be evidence that it strongly impacts performance on the measure and the measure must be specified so that the information about patient preference and the effect on the measure is transparent (e.g., numerator category computed separately, denominator exclusion category computed separately).

2e. For outcome measures and other measures (e.g., resource use) when indicated:

- an evidence-based risk-adjustment strategy (e.g., risk models, risk stratification) is specified and is based on patient clinical factors that influence the measured outcome (but not disparities in care) and are present at start of care;^{Error! Bookmark not defined.} OR

rationale/data support no risk adjustment.

AMA-PCPI Level I EHR Specifications

Clinical Topic	Hypertension
Measure Title	Blood Pressure Control
Measure #	PCPI HTN-1
Measure Description	Percentage of patients aged 18 years and older with a diagnosis of hypertension with a blood pressure <140/90 mm Hg OR patients with a blood pressure ≥140/90 mm Hg and prescribed 2 or more anti-hypertensive medications during the most recent office visit within a 12 month period
Measurement Period	Twelve consecutive months
Initial Patient Population	Patient Age: Patients aged 18 years and older before the start of the measurement period Diagnosis Active: Patient has a diagnosis of Hypertension before or simultaneously to encounter date Encounter: At least two visits with the physician, physician's assistant, or nurse practitioner during the measurement period
Denominator Statement	All patients aged 18 years and older with a diagnosis of hypertension
Numerator Statement	<p>Patients with a blood pressure <140/90 mm Hg* OR Patients with a blood pressure ≥ 140/90 mm Hg and prescribed** 2 or more anti-hypertensive medications during the most recent office visit within a 12 month period</p> <p><i>Report Number of Patients for Each Numerator Component Separately AND a Total</i></p> <p>*BP value used for measure calculation:</p> <ul style="list-style-type: none"> • Must be specified in medical record if >1 value (systolic/diastolic) recorded, and • Must be value upon which treatment decision was based, and • May be obtained by measurement during office visit, review of home blood pressure log, OR review of 24 hour ambulatory blood pressure monitor <p>**Prescribed may include prescriptions given to the patient for 2 or more anti-hypertensive medications at most recent office visit OR patient already taking 2 or more anti-hypertensive medications as documented in the current medication list (Each anti-hypertensive component in a combination medication should be counted individually)</p>
Denominator Exceptions	<p>Documentation of medical reason(s) for not prescribing 2 or more anti-hypertensive medications (eg, allergy, intolerant, postural hypotension, other medical reason)</p> <p>Documentation of patient reason(s) for not prescribing 2 or more anti-hypertensive medications (eg, patient declined, other patient reason)</p> <p>Documentation of system reason(s) for not prescribing 2 or more anti-hypertensive medications (eg, financial reasons, other system reason)</p>


AMA - PCPI Level I EHR Specifications

Measure Logic for Hypertension: Blood Pressure Control

Measure Description: Percentage of patients aged 18 years and older with a diagnosis of hypertension with a blood pressure <140/90 mm Hg OR patients with a blood pressure ≥ 140/90 mm Hg and prescribed 2 or more anti-hypertensive medications during the most recent office visit within a 12 month period

Measurement Period: 12 Consecutive Months

PCPI Measure #: HTN-1



PARAMETER SPECIFICATIONS (Value Sets are found in the Coding Appendices):

IPP: ¹ Patient Age: 18 years and older before the start of measurement period; ² Diagnosis, Active: before or simultaneously to encounter date; ³ Encounter: ≥ 2 visits during measurement period;

N: ^{4,5,6,7} Physical Exam Finding-during the most recent encounter in the measurement period; ⁸ Medication, Prescribed-active or ordered before or simultaneously to measurement period and count of ≥ 2 medications; ⁹ Medication, Prescribed-active or ordered before or simultaneously to measurement period and count of ≥ 1 medication;

E: Value Sets 000160, 000174, 000200 during the measurement period; all other Value Sets start before or simultaneously to measurement period. ^{10,11,12} Medication Allergy, Intolerance, Adverse effects-the Value Set listed references the medications to which the allergy, intolerance or adverse effect exists;

☼ Both (N) components (BP < 140/90 mmHg AND BP ≥ 140/90 mmHG with appropriate prescribing) should be reported separately in addition to the TOTAL (N)

*BP value used for measure calculation:

- Must be specified in medical record if >1 value (systolic/diastolic) recorded, and
- Must be value upon which treatment decision was based, and
- May be obtained by measurement during office visit, review of home blood pressure log, OR review of 24 hour ambulatory blood pressure monitor

*Coded examples are NOT intended to be an exhaustive list. Exceptions will vary for each patient and situation.

Basic Measure Calculation:

$$\frac{(N)}{(D) - (E)} = \%$$

The PCPI strongly recommends that exception rates also be computed and reported alongside performance rates as follows:

Exception Calculation:

$$\frac{(E)}{(D)} = \%$$

Exception Types:

E= E1 (Medical Exceptions) + E2 (Patient Exceptions) + E3 (System Exceptions)

For patients who have more than one valid exception, only one exception should be counted when calculating the exception rate

<p>Initial Patient Population (IPP)</p> <p>Definition: The initial patient population identifies the general group of patients that the performance measure is designed to address; usually focused on a specific clinical condition (e.g., coronary artery disease, asthma). For example, a patient aged 18 years and older with a diagnosis of CAD who has at least 2 Visits during the measurement period.</p>	<p>Denominator (D)</p> <p>Definition: The denominator defines the specific group of patients for inclusion in a specific performance measure based on specific criteria (e.g., patient's age, diagnosis, prior MI). In some cases, the denominator may be identical to the initial patient population.</p>	<p>Numerator (N)</p> <p>Definition: The numerator defines the group of patients in the denominator for whom a process or outcome of care occurs (e.g., flu vaccine received).</p>	<p>Denominator Exceptions (E)</p> <p>Definition: Denominator exceptions are the valid reasons why patients who are included in the denominator population did not receive a process or outcome of care (described in the numerator). Patients may have Denominator Exceptions for medical reasons (e.g., patient has an egg allergy so they did not receive flu vaccine); patient reasons (e.g., patient declined flu vaccine); or system reasons (e.g., patient did not receive flu Vaccine due to vaccine shortage). These cases are removed from the denominator population for the performance calculation, however the number of patients with valid exceptions should be calculated and reported. This group of patients constitutes the Denominator Exception reporting population – patients for whom the numerator was not achieved and there is a valid Denominator Exception.</p>
<p>Find the patients who meet the Initial Patient Population criteria (IPP)</p>	<p>Find the patients who qualify for the denominator (D):</p> <ul style="list-style-type: none"> ○ From the patients within the Patient Population criteria (IPP) select those people who meet Denominator selection criteria. <p>(In some cases the IPP and D are identical).</p>	<p>Find the patients who qualify for the Numerator (N):</p> <ul style="list-style-type: none"> ○ From the patients within the Denominator (D) criteria, select those people who meet Numerator selection criteria. ○ Validate that the number of patients in the numerator is less than or equal to the number of patients in the denominator 	<p>From the patients who did not meet the Numerator criteria, determine if the patient meets any criteria for the Denominator Exception (E1 + E2+E3). If they meet any criteria, they should be removed from the Denominator for performance calculation. As a point of reference, these cases are removed from the denominator population for the performance calculation, however the number of patients with valid exceptions should be calculated and reported.</p>

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000002	HTN	1	IPP	Encounter Outpatient	Encounter	CPT	99201	
000002	HTN	1	IPP	Encounter Outpatient	Encounter	CPT	99202	
000002	HTN	1	IPP	Encounter Outpatient	Encounter	CPT	99203	
000002	HTN	1	IPP	Encounter Outpatient	Encounter	CPT	99204	
000002	HTN	1	IPP	Encounter Outpatient	Encounter	CPT	99205	
000002	HTN	1	IPP	Encounter Outpatient	Encounter	CPT	99212	
000002	HTN	1	IPP	Encounter Outpatient	Encounter	CPT	99213	
000002	HTN	1	IPP	Encounter Outpatient	Encounter	CPT	99214	
000002	HTN	1	IPP	Encounter Outpatient	Encounter	CPT	99215	
000002	HTN	1	IPP	Encounter Outpatient	Encounter	CPT	99241	
000002	HTN	1	IPP	Encounter Outpatient	Encounter	CPT	99242	
000002	HTN	1	IPP	Encounter Outpatient	Encounter	CPT	99243	
000002	HTN	1	IPP	Encounter Outpatient	Encounter	CPT	99244	
000002	HTN	1	IPP	Encounter Outpatient	Encounter	CPT	99245	
000002	HTN	1	IPP	Encounter Nursing Facility	Encounter	CPT	99304	
000002	HTN	1	IPP	Encounter Nursing Facility	Encounter	CPT	99305	
000002	HTN	1	IPP	Encounter Nursing Facility	Encounter	CPT	99306	
000002	HTN	1	IPP	Encounter Nursing Facility	Encounter	CPT	99307	
000002	HTN	1	IPP	Encounter Nursing Facility	Encounter	CPT	99308	
000002	HTN	1	IPP	Encounter Nursing Facility	Encounter	CPT	99309	
000002	HTN	1	IPP	Encounter Nursing Facility	Encounter	CPT	99310	
000002	HTN	1	IPP	Encounter Outpatient	Encounter	CPT	99324	
000002	HTN	1	IPP	Encounter Outpatient	Encounter	CPT	99325	
000002	HTN	1	IPP	Encounter Outpatient	Encounter	CPT	99326	
000002	HTN	1	IPP	Encounter Outpatient	Encounter	CPT	99327	
000002	HTN	1	IPP	Encounter Outpatient	Encounter	CPT	99328	
000002	HTN	1	IPP	Encounter Outpatient	Encounter	CPT	99334	
000002	HTN	1	IPP	Encounter Outpatient	Encounter	CPT	99335	
000002	HTN	1	IPP	Encounter Outpatient	Encounter	CPT	99336	
000002	HTN	1	IPP	Encounter Outpatient	Encounter	CPT	99337	
000002	HTN	1	IPP	Encounter Outpatient	Encounter	CPT	99341	
000002	HTN	1	IPP	Encounter Outpatient	Encounter	CPT	99342	
000002	HTN	1	IPP	Encounter Outpatient	Encounter	CPT	99343	
000002	HTN	1	IPP	Encounter Outpatient	Encounter	CPT	99344	
000002	HTN	1	IPP	Encounter Outpatient	Encounter	CPT	99345	
000002	HTN	1	IPP	Encounter Outpatient	Encounter	CPT	99347	
000002	HTN	1	IPP	Encounter Outpatient	Encounter	CPT	99348	
000002	HTN	1	IPP	Encounter Outpatient	Encounter	CPT	99349	
000002	HTN	1	IPP	Encounter Outpatient	Encounter	CPT	99350	
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I9	401.0	MALIGNANT HYPERTENSION

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I9	401.1	BENIGN HYPERTENSION
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I9	401.9	HYPERTENSION NOS
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I9	402.00	MAL HYP HRT DIS W/O HF
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I9	402.01	MAL HYP HRT DIS W HF
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I9	402.10	BEN HYP HRT DIS W/O HF
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I9	402.11	BEN HYP HRT DIS W HF
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I9	402.90	HYP HRT DIS NOS W/O HF
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I9	402.91	HYP HRT DIS NOS W HF
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I9	403.00	MAL HYP REN DIS W/O RF
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I9	403.01	MAL HYP REN DIS W RF
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I9	403.10	BEN HYP REN DIS W/O RF
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I9	403.11	BEN HYP REN DIS W RF
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I9	403.90	HYP REN DIS NOS W/O RF
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I9	403.91	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I9	404.00	MAL HYP HRT/REN DIS W/O HF/RF
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I9	404.01	MAL HYP HRT/REN DIS W HF
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I9	404.02	MAL HYP HRT/REN DIS W RF
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I9	404.03	MAL HYP HRT/REN DIS W HF & RF
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I9	404.10	BEN HYP HRT/REN DIS W/O HF/RF
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I9	404.11	BEN HYP HRT/REN DIS W HF
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I9	404.12	BEN HYP HRT/REN DIS W RF
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I9	404.13	BEN HYP HRT/REN DIS W HF & RF
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I9	404.90	HYP HRT/REN DIS NOS W/O HF/RF
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I9	404.91	HYP HRT/REN DIS NOS W HF
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I9	404.92	HYP HRT/REN DIS NOS W RF
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I9	404.93	HYP HRT/REN DIS NOS W HF & RF
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I10	110	Essential (primary) hypertension
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I10	I11.0	Hypertensive heart disease with heart failure
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I10	I11.9	Hypertensive heart disease without heart failure
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I10	I12.0	Hypertensive chronic kidney disease with stage V chronic kidney disease or end stage renal disease
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I10	I12.9	Hypertensive chronic kidney disease with stage I through stage IV chronic kidney disease, or unspecified chronic kidney disease, NOS
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I10	113	Hypertensive heart and chronic kidney disease
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I10	I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage I through stage IV chronic kidney disease, or unspecified chronic kidney disease
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I10	I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage I through stage IV chronic kidney disease, or unspecified chronic kidney disease
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I10	I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage V chronic kidney disease, or end stage renal disease

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	I10	I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage V chronic kidney disease, or end stage renal disease
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	SNM	1201005	benign essential hypertension
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	SNM	10725009	benign hypertension
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	SNM	193003	benign hypertensive renal disease
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	SNM	78544004	chronic hypertensive uremia
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	SNM	48146000	diastolic hypertension
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	SNM	59621000	essential hypertension
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	SNM	429198000	exertional hypertension
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	SNM	62275004	hypertensive episode
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	SNM	86234004	hypertensive heart AND renal disease
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	SNM	38481006	hypertensive renal disease
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	SNM	194774006	hypertensive renal disease with renal failure
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	SNM	49220004	hypertensive renal failure
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	SNM	65518004	labile diastolic hypertension
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	SNM	371125006	labile essential hypertension
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	SNM	276789009	labile hypertension
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	SNM	78975002	malignant essential hypertension
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	SNM	70272006	malignant hypertension
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	SNM	65443008	malignant hypertensive renal disease
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	SNM	194793008	other specified hypertensive disease
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	SNM	84094009	rebound hypertension
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	SNM	59720008	sustained diastolic hypertension
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	SNM	429457004	systolic essential hypertension
000254	HTN	1	IPP	Hypertension	Diagnosis/Condition/Problem	SNM	56218007	systolic hypertension
000197	HTN	1	N	Systolic Blood Pressure	Physical Exam	SNM	271649006	systolic blood pressure
000198	HTN	1	N	Diastolic Blood Pressure	Physical Exam	SNM	271650006	diastolic blood pressure
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197475	Chlorothiazide 250 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	309198	Chlorothiazide 50 MG/ML Oral Suspension
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197476	Chlorothiazide 500 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	541298	Chlotride 500 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	213443	Diuril 250 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	213439	Diuril 50 MG/ML Oral Suspension
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	213447	Diuril 500 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197497	Chlorthalidone 100 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197498	Chlorthalidone 15 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197499	Chlorthalidone 25 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197500	Chlorthalidone 50 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831703	Hydone Tablet 25 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831701	Hydone Tablet 50 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	201263	Hygroton 100 MG Oral Tablet

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	214082	Hygroton 25 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	201262	Hygroton 50 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	214081	Thalitone 15 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	214083	Thalitone 25 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	310813	HCTZ 10 MG/ML Oral Solution
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197769	HCTZ 100 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	314020	HCTZ 100 MG/ML Oral Solution
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	199903	HCTZ 12.5 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	429503	HCTZ 12.5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	310798	HCTZ 25 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197770	HCTZ 50 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	207936	Esidrix 25 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	207942	Esidrix 50 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	207943	Ezide 50 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	207937	Hydro Par 25 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	207944	Hydro Par 50 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	542850	Hydrocot 50 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	207935	HydroDIURIL 100 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	207938	HydroDIURIL 25 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	207945	HydroDIURIL 50 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	542854	Hydrokraft 50 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	207946	Loqua 50 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	207939	Oretic 25 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	207947	Oretic 50 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	198110	Polythiazide 1 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	198111	Polythiazide 2 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	198112	Polythiazide 4 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	208716	Renese 1 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	208717	Renese 2 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	208719	Renese 4 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197815	Indapamide 1.25 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197816	Indapamide 2.5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	206945	Lozol 1.25 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	206946	Lozol 2.5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197977	Metolazone 0.5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197978	Metolazone 10 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197979	Metolazone 2.5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	311671	Metolazone 5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	93382	Mykrox 0.5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	207276	Zaroxolyn 10 MG Oral Tablet

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	207271	Zaroxolyn 2.5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	207272	Zaroxolyn 5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	250660	Bumetanide 0.2 MG/ML Oral Solution
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197417	Bumetanide 0.5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197418	Bumetanide 1 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197419	Bumetanide 2 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	104222	Bumetanide 5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	205488	Bumex 0.5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	205489	Bumex 1 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	205490	Bumex 2 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	251308	Furosemide 1 MG/ML Oral Solution
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197730	Furosemide 10 MG/ML Oral Solution
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	630032	Furosemide 12.5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	310429	Furosemide 20 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	104220	furosemide 20 MG per 5 ML Oral Solution
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	313988	Furosemide 40 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	248657	Furosemide 50 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	199610	Furosemide 500 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197732	Furosemide 80 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	542678	Furocot 40 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	205726	Lasix 10 MG/ML Oral Solution
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	200801	Lasix 20 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	200809	Lasix 40 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	205732	Lasix 80 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	205728	Lo-Aqua 40 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	630035	Salix - substance 12.5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	645036	Salix - substance 50 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	198369	torsemide 10 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	198370	torsemide 100 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	250044	torsemide 2.5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	198371	torsemide 20 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	198372	torsemide 5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	208076	Demadex 10 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	208080	Demadex 100 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	208081	Demadex 20 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	208082	Demadex 5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	977882	Midamor 5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	977887	Amiloride Hydrochloride 1 MG/ML Oral Solution
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	977880	Amiloride Hydrochloride 5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	198312	Triamterene 100 MG Oral Capsule

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	198313	Triamterene 50 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	208674	Dyrenium 100 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	208675	Dyrenium 50 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	351258	eplerenone 100 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	351256	eplerenone 25 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	351257	eplerenone 50 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	402106	Inspira 25 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	402105	Inspira 50 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	104231	spironolactone 10 MG per 5 ML Oral Suspension
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	198222	Spironolactone 100 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	313096	Spironolactone 25 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	104232	spironolactone 25 MG per 5 ML Oral Suspension
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	104230	spironolactone 5 MG per 5 ML Oral Suspension
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	198223	Spironolactone 50 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	104233	spironolactone 50 MG per 5 ML Oral Suspension
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	200825	Aldactone 100 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	200820	Aldactone 25 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	200817	Aldactone 50 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197379	Atenolol 100 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197380	Atenolol 25 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	755528	atenolol 25 MG per 5 ML Syrup
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197381	Atenolol 50 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	211773	Senormin 50 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	201322	Tenormin 100 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	150750	Tenormin 25 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	152414	Tenormin 50 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	261397	Betaxolol 10 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	261398	Betaxolol 20 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	213731	Kerlone 10 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	141882	Kerlone 20 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	865154	Bisoprolol Fumarate 1.25 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	854901	Bisoprolol Fumarate 10 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	865155	Bisoprolol Fumarate 2.5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	865157	Bisoprolol Fumarate 3.75 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	854905	Bisoprolol Fumarate 5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	865159	Bisoprolol Fumarate 7.5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	854903	Zebeta 10 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	854907	Zebeta 5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	866514	Metoprolol Tartrate 50 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	866511	Metoprolol Tartrate 100 MG Oral Tablet

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	866924	metoprolol tartrate 25 MG (as metoprolol succinate 23.75 MG) Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	866513	Lopressor 100 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	866516	Lopressor 50 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	866513	Lopressor 100 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	866516	Lopressor 50 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	866415	Metoprolol Tartrate 100 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	866419	metoprolol tartrate 200 MG (as metoprolol succinate 190 MG) 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	866422	Metoprolol Tartrate 200 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	866427	metoprolol tartrate 25 MG 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	866430	Metoprolol Tartrate 25 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	866436	metoprolol tartrate 50 MG (as metoprolol succinate 47.5 MG) 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	866439	Metoprolol Tartrate 50 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	866414	24 HR Toprol XL 100 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	866421	24 HR Toprol XL 200 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	866429	24 HR Toprol XL 25 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	866416	Toprol 100 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	866423	Toprol 200 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	866431	Toprol 25 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	866440	Toprol 50 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	866438	Toprol XL 50 MG 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	198004	Nadolol 120 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	198005	Nadolol 160 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	198006	Nadolol 20 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	198007	Nadolol 40 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	198008	Nadolol 80 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	206968	Nadolol 120 MG [Corgard]
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	201337	Nadolol 160 MG [Corgard]
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	201338	Nadolol 20 MG [Corgard]
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	208003	Nadolol 40 MG [Corgard]
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	208029	Nadolol 80 MG [Corgard]
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856448	Propranolol Hydrochloride 10 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856713	Propranolol Hydrochloride 160 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856719	Propranolol Hydrochloride 2 MG/ML Oral Solution
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856457	Propranolol Hydrochloride 20 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856724	propranolol hydrochloride 20 MG per 5 ML Oral Solution
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856519	Propranolol Hydrochloride 40 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856733	Propranolol Hydrochloride 40 MG per 5 ML Oral Solution
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856704	Propranolol Hydrochloride 5 MG per 5 ML Oral Syrup
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856703	Propranolol Hydrochloride 50 MG per 5 ML Oral Syrup

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856556	Propranolol Hydrochloride 60 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856735	Propranolol Hydrochloride 80 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856578	Propranolol Hydrochloride 80 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856712	Propranolol Hydrochloride 80 MG per 5 ML Oral Syrup
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856737	Propranolol Hydrochloride 80 MG/ML Oral Solution
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856739	Propranolol Hydrochloride 90 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856450	Inderal 10 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856508	Inderal 20 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856521	Inderal 40 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856557	Inderal 60 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856579	Inderal 80 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856459	Pronol 20 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856528	Pronol 40 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856460	propranolol hydrochloride 120 MG 24 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856463	Propranolol Hydrochloride 120 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856481	propranolol hydrochloride 160 MG 24 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856484	Propranolol Hydrochloride 160 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856535	propranolol hydrochloride 60 MG 24 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856538	Propranolol Hydrochloride 60 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856569	propranolol hydrochloride 80 MG 24 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856572	Propranolol Hydrochloride 80 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856464	Inderal 120 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856485	Inderal 160 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856539	Inderal 60 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856573	Inderal 80 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856462	Inderal LA 120 MG 24 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856483	Inderal LA 160 MG 24 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856537	Inderal LA 60 MG 24 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856571	Inderal LA 80 MG 24 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856472	InnoPran 120 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856577	InnoPran 80 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	856471	InnoPran XL 120 MG 24 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	198284	Timolol 10 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	198285	Timolol 20 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	198286	Timolol 5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	201340	Blocadren 10 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	208576	Blocadren 20 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	208575	Blocadren 5 MG Oral Tablet

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	998693	Acebutolol Hydrochloride 100 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	998689	Acebutolol Hydrochloride 200 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	998685	Acebutolol Hydrochloride 400 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	998695	Acebutolol Hydrochloride 400 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	998691	Sectral 200 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	998687	Sectral 400 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	312254	Penbutolol 20 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	207367	Levatol 20 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	198104	Pindolol 10 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	199277	Pindolol 15 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	198105	Pindolol 5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	208140	Visken 10 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	200857	Visken 5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	200032	carvedilol 12.5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	200033	carvedilol 25 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	686924	carvedilol 3.125 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	200031	carvedilol 6.25 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	860510	carvedilol phosphate 10 MG 24 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	860513	carvedilol phosphate 10 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	860516	carvedilol phosphate 20 MG 24 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	860519	carvedilol phosphate 20 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	860522	carvedilol phosphate 40 MG 24 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	860525	carvedilol phosphate 40 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	860532	carvedilol phosphate 80 MG 24 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	860535	carvedilol phosphate 80 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	860512	24 HR Coreg 10 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	860518	24 HR Coreg 20 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	860524	24 HR Coreg 40 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	860534	24 HR Coreg 80 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	860514	Coreg 10 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	212389	Coreg 12.5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	860520	Coreg 20 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	212390	Coreg 25 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	686926	Coreg 3.125 Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	860526	Coreg 40 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	212388	Coreg 6.25 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	860536	Coreg 80 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	896758	Labetalol hydrochloride 100 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	896762	Labetalol hydrochloride 200 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	896766	Labetalol hydrochloride 300 MG Oral Tablet

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	896983	Labetalol hydrochloride 400 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	896987	Labetalol hydrochloride 50 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	896760	Normodyne 100 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	896764	Normodyne 200 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	896768	Normodyne 300 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	896777	Trandate 100 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	896781	Trandate 200 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	896783	Trandate 300 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	308607	benazepril 10 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	308609	benazepril 20 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	308612	benazepril 40 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	308962	Captopril 100 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	308963	Captopril 12.5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	317173	Captopril 25 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	308964	Captopril 50 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	210994	Capoten 100 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	210994	Capoten 12.5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	201372	Capoten 25 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	201374	Capoten 50 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	858914	Enalapril Maleate 10 MG Chewable Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	858817	Enalapril Maleate 10 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	858920	Enalapril Maleate 2.5 MG Chewable Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	858804	Enalapril Maleate 2.5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	858938	Enalapril Maleate 5 MG Chewable Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	858813	Enalapril Maleate 5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	858845	Renitec 20 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	858819	Vasotec 10 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	858806	Vasotec 2.5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	858812	Vasotec 20 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	858815	Vasotec 5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	857169	Fosinopril Sodium 10 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	857183	Fosinopril Sodium 20 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	857187	Fosinopril Sodium 40 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	857171	Monopril 10 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	857185	Monopril 20 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	857189	Monopril 40 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	314076	Lisinopril 10 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	311353	Lisinopril 2.5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	314077	Lisinopril 20 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	205326	Lisinopril 30 MG Oral Tablet

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197884	Lisinopril 40 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	311354	Lisinopril 5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	206765	Prinivil 10 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	206763	Prinivil 2.5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	206766	Prinivil 20 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	206770	Prinivil 40 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	206770	Prinivil 5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	104377	Zestril 10 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	104375	Zestril 2.5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	104378	Zestril 20 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	213482	Zestril 30 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	206771	Zestril 40 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	104376	Zestril 5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	311734	moexipril 15 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	311735	moexipril 7.5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	206277	Univasc 15 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	206313	Univasc 7.5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	854984	Perindopril Erbumine 2 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	854988	Perindopril Erbumine 4 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	854925	Perindopril Erbumine 8 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	854986	Aceon 2 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	854990	Aceon 4 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	854927	Aceon 8 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	312748	quinapril (as quinapril hydrochloride) 10 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	312749	quinapril (as quinapril hydrochloride) 20 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	314203	quinapril (as quinapril hydrochloride) 40 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	312750	quinapril (as quinapril hydrochloride) 5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	207892	Accupril 10 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	207893	Accupril 20 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	207895	Accupril 40 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	207891	Accupril 5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845488	Ramipril 1.25 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	401965	Ramipril 1.25 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	261962	Ramipril 10 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	401968	Ramipril 10 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	198188	Ramipril 2.5 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	251856	Ramipril 2.5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	198189	Ramipril 5 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	251857	Ramipril 5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845489	Altace 1.25 MG Oral Capsule

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	730511	Altace 1.25 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	260333	Altace 10 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	730512	Altace 10 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	104384	Altace 2.5 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	730513	Altace 2.5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	104385	Altace 5 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	730514	Altace 5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	199622	trandolapril 0.5 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	199816	trandolapril 1 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	199353	trandolapril 1 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	199817	trandolapril 2 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	199351	trandolapril 2 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	210671	Mavik 1 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	210672	Mavik 2 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	210673	Mavik 4 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	639537	candesartan cilexetil 32 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	153822	candesartan cilexetil 4 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	153823	candesartan cilexetil 8 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	639539	Atacand 16 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	639543	Atacand 32 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	577785	Atacand 4 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	577787	Atacand 8 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	389185	eprosartan 300 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	310139	eprosartan 400 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	310140	eprosartan 600 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	261300	Teveten 400 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	261301	Teveten 600 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	200095	irbesartan 150 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	200096	irbesartan 300 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	200094	irbesartan 75 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	153666	Avapro 150 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	153667	Avapro 300 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	153665	Avapro 75 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	979480	Losartan Potassium 100 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	979485	Losartan Potassium 25 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	979492	Losartan Potassium 50 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	979482	Cozaar 100 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	979487	Cozaar 25 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	979494	Cozaar 50 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	401971	Olmесartan medoxomil 10 MG Oral Tablet

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	349401	Olmesartan medoxomil 20 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	349405	Olmesartan medoxomil 40 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	349373	Olmesartan medoxomil 5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	575927	Olmesartan medoxomil 20 MG [Benicar]
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	575928	Olmesartan medoxomil 40 MG [Benicar]
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	575926	Olmesartan medoxomil 5 MG [Benicar]
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	282755	telmisartan 20 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	205304	telmisartan 40 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	205305	telmisartan 80 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	284531	Micardis 20 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	213431	Micardis 40 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	213432	Micardis 80 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	199919	valsartan 160 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	349201	valsartan 160 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	349200	valsartan 320 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	153077	valsartan 40 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	349483	valsartan 40 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	199850	valsartan 80 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	349199	valsartan 80 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	153080	Diovan 160 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	351762	Diovan 160 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	352001	Diovan 320 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	352274	Diovan 40 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	153079	Diovan 80 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	351761	Diovan 80 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	830872	diltiazem hydrochloride 120 MG 12 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	830861	diltiazem hydrochloride 120 MG 24 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	830874	diltiazem hydrochloride 120 MG 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831150	Diltiazem Hydrochloride 120 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831117	Diltiazem Hydrochloride 120 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831054	Diltiazem Hydrochloride 120 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	830845	diltiazem hydrochloride 180 MG 24 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	830877	diltiazem hydrochloride 180 MG 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831233	Diltiazem Hydrochloride 180 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831230	Diltiazem Hydrochloride 180 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831229	Diltiazem Hydrochloride 180 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	833716	diltiazem hydrochloride 200 MG 24 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845214	Diltiazem Hydrochloride 200 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	830837	diltiazem hydrochloride 240 MG 24 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	830879	diltiazem hydrochloride 240 MG 24 HR Extended Release Tablet

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831274	Diltiazem Hydrochloride 240 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831271	Diltiazem Hydrochloride 240 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	833217	Diltiazem Hydrochloride 30 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	830801	diltiazem hydrochloride 300 MG 24 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	830882	diltiazem hydrochloride 300 MG 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831313	Diltiazem Hydrochloride 300 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831312	Diltiazem Hydrochloride 300 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	830795	Diltiazem Hydrochloride 360 MG 24 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	830897	diltiazem hydrochloride 360 MG 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831339	Diltiazem Hydrochloride 360 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845184	Diltiazem Hydrochloride 360 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831359	diltiazem hydrochloride 420 MG 24 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	830900	diltiazem hydrochloride 420 MG 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831351	Diltiazem Hydrochloride 420 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831350	Diltiazem Hydrochloride 420 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	830865	diltiazem hydrochloride 60 MG 12 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	833707	diltiazem hydrochloride 60 MG 12 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	830922	Diltiazem Hydrochloride 60 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	830979	Diltiazem Hydrochloride 60 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831012	Diltiazem Hydrochloride 60 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831103	Diltiazem Hydrochloride 60 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	830869	diltiazem hydrochloride 90 MG 12 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	833708	diltiazem hydrochloride 90 MG 12 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831022	Diltiazem Hydrochloride 90 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831022	Diltiazem Hydrochloride 90 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831102	Diltiazem Hydrochloride 90 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	849860	Diltiazem Malate 240 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	830873	12 HR Cardizem 120 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	830867	12 HR Cardizem 60 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	830871	12 HR Cardizem 90 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	830863	24 HR Cardizem 120 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	830876	24 HR Cardizem 120 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	830847	24 HR Cardizem 180 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	830878	24 HR Cardizem 180 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	830839	24 HR Cardizem 240 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	830880	24 HR Cardizem 240 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	830803	24 HR Cardizem 300 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	830883	24 HR Cardizem 300 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	830798	24 HR Cardizem 360 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	830898	24 HR Cardizem 360 MG Extended Release Tablet

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	830902	24 HR Cardizem 420 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831226	24 HR Cartia 120 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831255	24 HR Cartia 180 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831309	24 HR Cartia 240 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831338	24 HR Cartia 300 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831224	24 HR Dilacor 120 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831254	24 HR Dilacor 180 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831305	24 HR Dilacor 240 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831252	24 HR Dilt 120 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831285	24 HR Dilt 180 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831337	24 HR Dilt 240 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831250	24 HR Dilt 300 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831302	24 HR Diltia 180 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831209	24 HR Diltia 240 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	848524	24 HR Diltia XT 120 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	848524	24 HR Diltzac 120 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	833703	24 HR Diltzac 180 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	833704	24 HR Diltzac 240 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	833705	24 HR Diltzac 300 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	833706	24 HR Diltzac 360 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831196	24 HR Tazia 120 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831248	24 HR Tazia 180 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831300	24 HR Tazia 240 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831325	24 HR Tazia 300 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831349	24 HR Tazia 360 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	833694	24 HR Tiamate 120 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	833695	24 HR Tiamate 180 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	833696	24 HR Tiamate 240 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831193	24 HR Tiazac 120 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831244	24 HR Tiazac 180 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831296	24 HR Tiazac 240 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831323	24 HR Tiazac 300 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831323	24 HR Tiazac 360 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845176	Cardizem 120 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845180	Cardizem 120 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831055	Cardizem 120 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845175	Cardizem 180 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845181	Cardizem 180 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845174	Cardizem 240 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845182	Cardizem 240 MG Extended Release Tablet

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	833219	Cardizem 30 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845173	Cardizem 300 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845183	Cardizem 300 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845172	Cardizem 360 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845185	Cardizem 360 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845186	Cardizem 420 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845177	Cardizem 60 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	834393	Cardizem 60 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845178	Cardizem 90 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831137	Cardizem 90 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845192	Cartia 120 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831242	Cartia 180 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831288	Cartia 240 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831321	Cartia 300 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845191	Dilacor 120 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845197	Dilacor 180 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845202	Dilacor 240 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845190	Dilt 120 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845196	Dilt 180 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845198	Dilt 240 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845205	Dilt 300 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845189	Diltia 120 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845195	Diltia 180 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845201	Diltia 240 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831172	Diltzac 120 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831240	Diltzac 180 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831282	Diltzac 240 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831319	Diltzac 300 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831345	Diltzac 360 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845188	Taztia 120 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845194	Taztia 180 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845200	Taztia 240 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845204	Taztia 300 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845207	Taztia 360 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	846148	Teczem Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831119	Tiamate 120 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831232	Tiamate 180 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831273	Tiamate 240 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845187	Tiazac 120 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845193	Tiazac 180 MG Extended Release Capsule

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845199	Tiazac 240 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845203	Tiazac 300 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845206	Tiazac 360 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	831360	Tiazac 420 MG 24 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845208	Tiazac 420 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897666	Verapamil hydrochloride 120 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	901438	Verapamil hydrochloride 160 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	898340	Verapamil hydrochloride 180 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	901446	Verapamil hydrochloride 240 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897722	Verapamil hydrochloride 40 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	901450	verapamil hydrochloride 40 MG per 5 ML Oral Solution
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897683	Verapamil hydrochloride 80 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897635	verapamil 180 MG 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897646	verapamil 240 MG 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897584	verapamil hydrochloride 100 MG 24 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897587	Verapamil hydrochloride 100 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	901434	verapamil hydrochloride 120 MG 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897612	verapamil hydrochloride 120 MG 24HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897615	Verapamil hydrochloride 120 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897659	Verapamil hydrochloride 120 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897618	verapamil hydrochloride 180 MG 24 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897621	Verapamil hydrochloride 180 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897640	Verapamil hydrochloride 180 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897590	verapamil hydrochloride 200 MG 24 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897593	Verapamil hydrochloride 200 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897624	verapamil hydrochloride 240 MG 24HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897627	Verapamil hydrochloride 240 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897649	Verapamil hydrochloride 240 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897596	verapamil hydrochloride 300 MG 24 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897599	Verapamil hydrochloride 300 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897630	verapamil hydrochloride 360 MG 24 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897633	Verapamil hydrochloride 360 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897719	Verapamil hydrochloride 40 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	901448	Verapamil hydrochloride 400 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897635	verapamil 180 MG 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897646	verapamil 240 MG 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897584	verapamil hydrochloride 100 MG 24 HR Extended Release Capsule

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897587	Verapamil hydrochloride 100 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	901434	verapamil hydrochloride 120 MG 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897612	verapamil hydrochloride 120 MG 24HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897615	Verapamil hydrochloride 120 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897659	Verapamil hydrochloride 120 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897666	Verapamil hydrochloride 120 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	901438	Verapamil hydrochloride 160 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897618	verapamil hydrochloride 180 MG 24 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897621	Verapamil hydrochloride 180 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897640	Verapamil hydrochloride 180 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	898340	Verapamil hydrochloride 180 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897590	verapamil hydrochloride 200 MG 24 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897593	Verapamil hydrochloride 200 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897624	verapamil hydrochloride 240 MG 24HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897627	Verapamil hydrochloride 240 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897649	Verapamil hydrochloride 240 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	901446	Verapamil hydrochloride 240 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897596	verapamil hydrochloride 300 MG 24 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897599	Verapamil hydrochloride 300 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897630	verapamil hydrochloride 360 MG 24 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897633	Verapamil hydrochloride 360 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897719	Verapamil hydrochloride 40 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897722	Verapamil hydrochloride 40 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	901450	verapamil hydrochloride 40 MG per 5 ML Oral Solution
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	901448	Verapamil hydrochloride 400 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	897683	Verapamil hydrochloride 80 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	757675	Amlodipine 2.5 MG Disintegrating Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	757675	Amlodipine 5 MG Disintegrating Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	757674	Amlodipine 10 MG Disintegrating Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	308135	amlodipine (as amlodipine besylate) 10 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	308136	amlodipine (as amlodipine besylate) 2.5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197361	amlodipine (as amlodipine besylate) 5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	212575	Norvasc 10 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	212542	Norvasc 2.5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	212549	Norvasc 5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	402695	Felodipine 10 MG 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	700745	Felodipine 10 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	402698	Felodipine 2.5 MG 24 HR Extended Release Tablet

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197692	Felodipine 2.5 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	402696	felodipine 5 MG 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	358334	Felodipine 5 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	104420	24 HR Plendil 10 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	152933	24 HR Plendil 2.5 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	104419	24 HR Plendil 5 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	844418	Plendil 10 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	844437	Plendil 2.5 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	844417	Plendil 5 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	562518	isradipine 10 MG 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	311202	Isradipine 10 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197848	Isradipine 2.5 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	199757	Isradipine 2.5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	562520	isradipine 5 MG 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	311203	Isradipine 5 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197849	Isradipine 5 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	885733	24 HR Dynacirc 10 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	885735	24 HR Dynacirc 5 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	885734	Dynacirc 10 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	206935	Dynacirc 2.5 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	885736	Dynacirc 5 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	206934	Dynacirc 5 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	858587	nicardipine hydrochloride 30 MG 12 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	858590	Nicardipine hydrochloride 30 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	858580	nicardipine hydrochloride 45 MG 12 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	858584	Nicardipine hydrochloride 45 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	858593	nicardipine hydrochloride 60 MG 12 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	858596	Nicardipine hydrochloride 60 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	250206	nifedipine 10 MG 12 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	248708	nifedipine 10 MG 12 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	844748	Nifedipine 10 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	844741	Nifedipine 10 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	249620	nifedipine 20 MG 12 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	844745	Nifedipine 20 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	246262	Nifedipine 20 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	227058	nifedipine 30 MG 24 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	198034	nifedipine 30 MG 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	844724	Nifedipine 30 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	491070	Nifedipine 30 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	250384	nifedipine 40 MG 24 HR Extended Release Tablet

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	844750	Nifedipine 40 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	227059	nifedipine 60 MG 24 HR Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	198035	nifedipine 60 MG 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	844725	Nifedipine 60 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	491078	Nifedipine 60 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	198036	nifedipine 90 MG 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	491086	Nifedipine 90 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	672916	24 HR Adalat 30 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	672917	24 HR Adalat 60 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	672918	24 HR Adalat 90 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	672921	24 HR Afeditab CR 60 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	880433	24 HR Nifediac CC 30 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	541603	24 HR Nifediac CC 60 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	880437	24 HR Nifediac CC 90 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	360394	24 HR Nifedical 30 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	351438	24 HR Nifedical 60 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	207772	24 HR Procardia 30 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	207773	24 HR Procardia 60 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	207774	24 HR Procardia 90 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845004	Adalat 30 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845005	Adalat 60 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845006	Adalat 90 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	672920	Afeditab CR 30 MG 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845007	Afeditab CR 30 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845008	Afeditab CR 60 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	880434	Nifediac 30 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	844923	Nifediac 60 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	880438	Nifediac 90 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	844846	Nifedical 30 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	844830	Nifedical 60 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	844584	Procardia 30 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	844585	Procardia 60 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	844586	Procardia 90 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	311983	nisoldipine 10 MG 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	562154	Nisoldipine 10 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	763519	nisoldipine 17 MG 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845095	Nisoldipine 17 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	311984	nisoldipine 20 MG 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	562514	Nisoldipine 20 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	763574	nisoldipine 25.5 MG 24 HR Extended Release Tablet

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845097	Nisoldipine 25.5 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	311985	nisoldipine 30 MG 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	562515	Nisoldipine 30 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	763589	nisoldipine 34 MG 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845101	Nisoldipine 34 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	360344	nisoldipine 40 MG 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	311986	Nisoldipine 40 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	790489	nisoldipine 8.5 MG 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	763497	Nisoldipine 8.5 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	672922	24 HR Sular 10 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	763521	24 HR Sular 17 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	597921	24 HR Sular 20 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	763576	24 HR Sular 25.5 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	597922	24 HR Sular 30 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	763591	24 HR Sular 34 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	597923	24 HR Sular 40 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	790840	24 HR Sular 8.5 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845009	Sular 10 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845096	Sular 17 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	844942	Sular 20 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	844942	Sular 25.5 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	844943	Sular 30 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	845102	Sular 34 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	844944	Sular 40 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	763499	Sular 8.5 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197625	Doxazosin 1 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197626	Doxazosin 2 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	636360	doxazosin 4 MG 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	389131	Doxazosin 4 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197627	Doxazosin 4 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	636361	doxazosin 8 MG 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	389166	Doxazosin 8 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197628	Doxazosin 8 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	104367	Cardura 1 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	104368	Cardura 2 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	631240	Cardura 4 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	104369	Cardura 4 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	631243	Cardura 8 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	205544	Cardura 8 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	199796	Prazosin 0.5 MG Oral Tablet

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	312593	Prazosin 1 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	199797	Prazosin 1 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	312594	Prazosin 2 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	199798	Prazosin 2 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	198141	Prazosin 5 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	199799	Prazosin 5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	208979	Minipress 1 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	208980	Minipress 2 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	208981	Minipress 5 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	313215	terazosin (as terazosin hydrochloride) 1 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	313216	terazosin (as terazosin hydrochloride) 1 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	260376	terazosin (as terazosin hydrochloride) 10 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	313214	terazosin (as terazosin hydrochloride) 10 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	313217	terazosin (as terazosin hydrochloride) 2 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	313218	terazosin (as terazosin hydrochloride) 2 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	313219	terazosin (as terazosin hydrochloride) 5 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	313220	terazosin (as terazosin hydrochloride) 5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	1013930	12 HR Clonidine Hydrochloride 0.1 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	1013937	12 HR Clonidine Hydrochloride 0.2 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	892791	Clonidine Hydrochloride 0.025 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	1013894	Clonidine Hydrochloride 0.1 MG Enteric Coated Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	885878	clonidine hydrochloride 0.1 MG/ML (clonidine 0.09 MG/ML) 24HR Extended Release Oral Suspension
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	885879	Clonidine Hydrochloride 0.1 MG/ML Extended Release Suspension
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	885880	clonidine hydrochloride 0.2 MG (clonidine 0.17 MG) 24HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	885881	Clonidine Hydrochloride 0.2 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	892795	Clonidine Hydrochloride 0.25 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	885882	clonidine hydrochloride 0.3 MG (clonidine 0.26 MG) 24HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	885883	Clonidine Hydrochloride 0.3 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	884173	clonidine hydrochloride 100 MCG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	884221	clonidine hydrochloride 100 MCG/ML Injectable Solution
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	884185	clonidine hydrochloride 200 MCG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	884189	clonidine hydrochloride 300 MCG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	1013934	12 HR Kapvay 0.1 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	1013939	12 HR Kapvay 0.2 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	884175	Catapres 0.1 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	884187	Catapres 0.2 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	884191	Catapres 0.3 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	998673	Catapres-TTS-1 0.1 MG/Day Weekly Transdermal Patch
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	998677	Catapres-TTS-2 0.2 MG/Day Weekly Transdermal Patch

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	998681	Catapres-TTS-3 0.3 MG/Day Weekly Transdermal Patch
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	998671	clonidine hydrochloride 0.1 MG/Day Weekly Transdermal Patch
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	998675	clonidine hydrochloride 0.2 MG/Day Weekly Transdermal Patch
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	998679	clonidine hydrochloride 0.3 MG/Day Weekly Transdermal Patch
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	104357	Methyldopa 250 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197955	Methyldopa 125 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197956	Methyldopa 250 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197957	Methyldopa 50 MG/ML Oral Suspension
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197958	Methyldopa 500 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	311645	Methyldopa 250 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	411773	Methyldopa 350 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	411774	Methyldopa 250 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	411775	Methyldopa 175 MG Extended Release Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	201354	Aldomet 125 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	201355	Aldomet 250 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	201361	Aldomet 50 MG/ML Oral Suspension
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	201358	Aldomet 500 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	198196	Reserpine 0.1 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	198197	Reserpine 0.25 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	315197	Reserpine 1 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	429105	Reserpine 0.5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	208085	Hydropres-25 Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	208091	Hydropres-50 Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197745	Guanfacine 1 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197746	Guanfacine 2 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	862006	24 HR Guanfacine 1 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	862013	24 HR Guanfacine 2 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	862019	24 HR Guanfacine 3 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	862025	24 HR Guanfacine 4 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	862011	Guanfacine 1 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	862016	Guanfacine 2 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	862022	Guanfacine 3 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	862028	Guanfacine 4 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	862010	Intuniv 1 MG 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	862012	Intuniv 1 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	862012	Intuniv 2 MG 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	862017	Intuniv 2 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	862021	Intuniv 3 MG 24 HR Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	862023	Intuniv 3 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	862027	Intuniv 4 MG 24 HR Extended Release Tablet

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	862029	Intuniv 4 MG Extended Release Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	206412	Tenex 1 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	206413	Tenex 2 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	905199	Hydralazine Hydrochloride 10 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	905222	Hydralazine Hydrochloride 100 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	905225	Hydralazine Hydrochloride 25 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	905395	Hydralazine Hydrochloride 50 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	966620	Hydralazine Hydrochloride 50 MG Oral Capsule
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	905201	Apresoline 10 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	905224	Apresoline 100 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	905227	Apresoline 25 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	905397	Apresoline 50 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197986	Minoxidil 10 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	197987	Minoxidil 2.5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	199776	Minoxidil 5 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	201350	Loniten 10 MG Oral Tablet
000261	HTN	1	N	Single Agent Anti-Hypertensive	Medication	RxNorm	201348	Loniten 2.5 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898342	Amlodipine 10 MG / Benazepril hydrochloride 20 MG Oral Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898346	Amlodipine 10 MG / Benazepril hydrochloride 40 MG Oral Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898350	Amlodipine 2.5 MG / Benazepril hydrochloride 10 MG Oral Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898353	Amlodipine 5 MG / Benazepril hydrochloride 10 MG Oral Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898356	Amlodipine 5 MG / Benazepril hydrochloride 20 MG Oral Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898359	Amlodipine 5 MG / Benazepril hydrochloride 40 MG Oral Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898344	Lotrel 10/20 Oral Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898348	Lotrel 10/40 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898352	Lotrel 2.5/10 Oral Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898355	Lotrel 5/10 Oral Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898358	Lotrel 5/20 Oral Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898361	Lotrel 5/40 Oral Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	858618	Enalapril Maleate 5 MG / Felodipine 2.5 MG Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	858621	Enalapril Maleate 5 MG / Felodipine 5 MG Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	858884	Lexxel 5/2.5 Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	858892	Lexxel 5/5 Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897781	trandolapril 1 MG / verapamil hydrochloride 240 MG 24 HR Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897778	trandolapril 1 MG / Verapamil hydrochloride 240 MG Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897783	trandolapril 2 MG / verapamil hydrochloride 180 MG 24 HR Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	901451	trandolapril 2 MG / Verapamil hydrochloride 180 MG Extended Release Capsule

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897786	trandolapril 2 MG / Verapamil hydrochloride 180 MG Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897844	trandolapril 2 MG / verapamil hydrochloride 240 MG 24 HR Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897847	trandolapril 2 MG / Verapamil hydrochloride 240 MG Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897853	trandolapril 4 MG / Verapamil hydrochloride 240 MG 24 HR Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897856	trandolapril 4 MG / Verapamil hydrochloride 240 MG Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897782	Tarka 1/240 24 HR Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897785	Tarka 2/180 24 HR Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897846	Tarka 2/240 24 HR Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897855	Tarka 4/240 24 HR Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897780	trandolapril 1 MG / Verapamil hydrochloride 240 MG Extended Release Tablet [Tarka 1/240]
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897787	trandolapril 2 MG / Verapamil hydrochloride 180 MG Extended Release Tablet [Tarka 2/180]
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897848	trandolapril 2 MG / Verapamil hydrochloride 240 MG Extended Release Tablet [Tarka 2/240]
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897857	trandolapril 4 MG / Verapamil hydrochloride 240 MG Extended Release Tablet [Tarka 4/240]
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898362	benazepril hydrochloride 10 MG / HCTZ 12.5 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898367	benazepril hydrochloride 20 MG / HCTZ 12.5 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898372	Benazepril hydrochloride 20 MG / Hydrochlorothiazide 25 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898378	Benazepril hydrochloride 5 MG / Hydrochlorothiazide 6.25 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898371	Lotensin HCT (benazepril 20 MG / HCTZ 12.5 MG) Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898376	Lotensin HCT (benazepril 20 MG / HCTZ 25 MG) Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898366	Lotensin HCT 10/12.5 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898382	Lotensin HCT 5/6.25 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	104370	captopril 25 MG / HCTZ 12.5 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197436	captopril 25 MG / HCTZ 15 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197437	captopril 25 MG / HCTZ 25 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197438	captopril 50 MG / HCTZ 15 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197439	captopril 50 MG / HCTZ 25 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	211053	Capozide 25/15 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	211072	Capozide 25/25 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	790297	Capozide 50/15 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	790296	Capozide 50/25 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	858913	enalapril maleate 10 MG / HCTZ 25 MG Chewable Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	858828	enalapril maleate 10 MG / HCTZ 25 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	858921	enalapril maleate 20 MG / HCTZ 12.5 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	858935	enalapril maleate 5 MG / HCTZ 12.5 MG Chewable Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	858824	enalapril maleate 5 MG / HCTZ 12.5 MG Oral Tablet

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	858827	Vaseretic (enalapril maleate 5 MG / HCTZ 12.5 MG) Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	858830	Vaseretic 10/25 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	857166	fosinopril sodium 10 MG / HCTZ 12.5 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	857174	fosinopril sodium 20 MG / HCTZ 12.5 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	857182	Monopril-HCT 10/12.5 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	857178	Monopril-HCT 20/12.5 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197885	HCTZ 12.5 MG / lisinopril 10 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197886	HCTZ 12.5 MG / lisinopril 20 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197887	HCTZ 25 MG / lisinopril 20 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	1001394	Hydrochlorothiazide 12.5 MG / Lisinopril 5 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	207963	Prinzide (HCTZ 12.5 MG / lisinopril 20 MG) Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	207961	Prinzide (lisinopril 10 MG / HCTZ 12.5 MG) Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	207965	Prinzide (lisinopril 20 MG / HCTZ 25 MG) Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	207965	Zestoretic 10/12.5 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	823982	Zestoretic 20/12.5 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	823971	Zestoretic 20/25 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	349443	HCTZ 12.5 MG / moexipril 15 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	310795	HCTZ 12.5 MG / moexipril 7.5 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	310805	HCTZ 25 MG / moexipril 15 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	891618	Uniretic 15/12.5 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	891626	Uniretic 15/25 (moexipril / HCTZ) Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	891622	Uniretic 7.5/12.5 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	310796	HCTZ 12.5 MG / quinapril 10 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	310797	HCTZ 12.5 MG / quinapril 20 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	310809	HCTZ 25 MG / quinapril 20 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	809854	Accuretic 10/12.5 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	809858	Accuretic 20/12.5 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	882559	Accuretic 20/25 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	991549	Quinaretic 10/12.5 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	991553	Quinaretic 20/12.5 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	991557	Quinaretic 20/25 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	578325	candesartan cilexetil 16 MG / HCTZ 12.5 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	578330	candesartan cilexetil 32 MG / HCTZ 12.5 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	802749	candesartan cilexetil 32 MG / HCTZ 25 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	805863	Atacand HCT 16/12.5 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	805859	Atacand HCT 32/12.5 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	805855	Atacand HCT 32/25 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	351292	eprosartan 600 MG / HCTZ 12.5 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	351293	eprosartan 600 MG / HCTZ 25 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	352335	Teveten HCT (eprosartan 600 MG / HCTZ 12.5 MG) Oral Tablet

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	352336	Teveten HCT (eprosartan 600 MG / HCTZ 25 MG) Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	310792	HCTZ 12.5 MG / irbesartan 150 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	310793	HCTZ 12.5 MG / irbesartan 300 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	485471	HCTZ 25 MG / irbesartan 300 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	823934	Avalide 150/12.5 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	823938	Avalide 300/12.5 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	823942	Avalide 300/25 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	979464	HCTZ 12.5 MG / losartan potassium 100 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	979468	HCTZ 12.5 MG / losartan potassium 50 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	979471	HCTZ 25 MG / losartan potassium 100 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	979466	Hyzaar 100/12.5 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	979473	Hyzaar 100/25 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	979470	Hyzaar 50/12.5 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	403853	HCTZ 12.5 MG / olmesartan medoxomil 20 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	403854	HCTZ 12.5 MG / olmesartan medoxomil 40 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	403855	HCTZ 25 MG / olmesartan medoxomil 40 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	847060	Benicar HCT 20/12.5 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	847055	Benicar HCT 40/12.5 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	847042	Benicar HCT 40/25 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	283316	HCTZ 12.5 MG / telmisartan 40 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	283317	HCTZ 12.5 MG / telmisartan 80 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	477130	HCTZ 25 MG / telmisartan 80 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	749833	Micardis-HCT 40/12.5 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	749837	Micardis-HCT 80/12.5 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	749841	Micardis-HCT 80/25 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	200285	HCTZ 12.5 MG / valsartan 160 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	636042	HCTZ 12.5 MG / valsartan 320 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	200284	HCTZ 12.5 MG / valsartan 80 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	349353	HCTZ 25 MG / valsartan 160 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	636045	HCTZ 25 MG / valsartan 320 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	809018	Diovan HCT 160/12.5 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	809022	Diovan HCT 160/25 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	809026	Diovan HCT 320/12.5 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	809030	Diovan HCT 320/25 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	809014	Diovan HCT 80/12.5 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197382	Atenolol 100 MG / Chlorthalidone 25 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	152916	Atenolol 50 MG / Chlorthalidone 12.5 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197383	Atenolol 50 MG / Chlorthalidone 25 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	746023	Tenoretic 100 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	746030	Tenoretic 50 Oral Tablet

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	854908	bisoprolol fumarate 10 MG / HCTZ 6.25 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	854916	bisoprolol fumarate 2.5 MG / HCTZ 6.25 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	854919	bisoprolol fumarate 5 MG / HCTZ 6.25 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	854910	Ziac 10/6.25 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	854918	Ziac 2.5/6.25 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	854921	Ziac 5/6.25 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866461	HCTZ 12.5 MG / metoprolol tartrate 25 MG 24 HR Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866472	HCTZ 12.5 MG / metoprolol tartrate 50 MG 24 HR Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866479	HCTZ 25 MG / metoprolol tartrate 100 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866846	HCTZ 25 MG / metoprolol tartrate 200 MG (as metoprolol succinate 190 MG) 24 HR Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866482	HCTZ 25 MG / metoprolol tartrate 50 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866491	HCTZ 50 MG / metoprolol tartrate 100 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866452	hydrochlorothiazide 12.5 MG / metoprolol tartrate 100 MG (as metoprolol succinate 95 MG) 24 HR Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866456	Hydrochlorothiazide 12.5 MG / Metoprolol Tartrate 100 MG Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866465	Hydrochlorothiazide 12.5 MG / Metoprolol Tartrate 25 MG Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866476	Hydrochlorothiazide 12.5 MG / Metoprolol Tartrate 50 MG Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866455	Dutoprol 100/12.5 MG 24 HR Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866464	Dutoprol 25/12.5 MG 24 HR Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866475	Dutoprol 50/12.5 24 HR Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866457	Hydrochlorothiazide 12.5 MG / Metoprolol Tartrate 100 MG Extended Release Tablet [Dutoprol 100/12.5]
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866466	Hydrochlorothiazide 12.5 MG / Metoprolol Tartrate 25 MG Extended Release Tablet [Dutoprol 25/12.5]
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866477	Hydrochlorothiazide 12.5 MG / Metoprolol Tartrate 50 MG Extended Release Tablet [Dutoprol 50/12.5]
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866498	Lopressor HCT 100/25 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866506	Lopressor HCT 100/50 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866502	Lopressor HCT 50/25 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	198000	Bendroflumethiazide 5 MG / Nadolol 40 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	198001	Bendroflumethiazide 5 MG / Nadolol 80 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	208003	Corzide 40/5 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	208029	Corzide 80/5 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	856398	24 HR Hydrochlorothiazide 50 MG / Propranolol Hydrochloride 120 MG Extended Release Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	856401	24 HR Hydrochlorothiazide 50 MG / Propranolol Hydrochloride 160 MG Extended Release Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	856412	24 HR Hydrochlorothiazide 50 MG / Propranolol Hydrochloride 80 MG Extended Release Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	856422	HCTZ 25 MG / propranolol hydrochloride 40 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	856429	HCTZ 25 MG / propranolol hydrochloride 80 MG Oral Tablet

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	856393	HCTZ 50 MG / propranolol hydrochloride 120 MG Extended Release Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	856406	HCTZ 50 MG / propranolol hydrochloride 160 MG Extended Release Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	856417	HCTZ 50 MG / propranolol hydrochloride 80 MG Extended Release Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	856426	Inderide 40/25 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	856433	Inderide 80/25 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	856586	Inderide LA 120/50 24 HR Extended Release Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	856587	Inderide LA 120/50 Extended Release Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	856591	Inderide LA 160/50 24 HR Extended Release Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	856592	Inderide LA 160/50 Extended Release Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	856596	Inderide LA 80/50 24 HR Extended Release Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	856597	Inderide LA 80/50 Extended Release Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	310811	HCTZ 25 MG / timolol 10 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	491234	Timolide (HCTZ 25 MG / timolol 10 MG) Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197963	HCTZ 15 MG / methyldopa 250 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197960	HCTZ 25 MG / methyldopa 250 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197962	HCTZ 30 MG / methyldopa 500 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197961	HCTZ 50 MG / methyldopa 500 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	688643	Aldoril (HCTZ 15 MG / methyldopa 250 MG) Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	688645	Aldoril (HCTZ 25 MG / methyldopa 250 MG) Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	688647	Aldoril (HCTZ 30 MG / methyldopa 500 MG) Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	688649	Aldoril (HCTZ 50 MG / methyldopa 500 MG) Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	205364	Chlorthalidone 25 MG / Reserpine 0.125 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	205365	Chlorthalidone 50 MG / Reserpine 0.25 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	214094	Chlorthalidone 25 MG / Reserpine 0.125 MG Oral Tablet [Demi-Regroton]
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	214095	Chlorthalidone 50 MG / Reserpine 0.25 MG Oral Tablet [Regroton]
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	237192	Chlorothiazide 250 MG / Reserpine 0.125 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197477	Chlorothiazide 500 MG / Reserpine 0.125 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	213504	Chlorothiazide 250 MG / Reserpine 0.125 MG Oral Tablet [Diupres-250]
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	213505	Chlorothiazide 500 MG / Reserpine 0.125 MG Oral Tablet [Diupres-500]
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	310810	HCTZ 25 MG / reserpine 0.1 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	204501	HCTZ 25 MG / reserpine 0.125 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	314018	HCTZ 50 MG / reserpine 0.1 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197771	HCTZ 50 MG / reserpine 0.125 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	208084	Hydrochlorothiazide 25 MG / Reserpine 0.125 MG Oral Tablet [Hydro-Reserp]
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	208086	Hydrochlorothiazide 25 MG / Reserpine 0.125 MG Oral Tablet [Hydroserp]
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	208087	Hydrochlorothiazide 25 MG / Reserpine 0.125 MG Oral Tablet [Hydroserpine #1]

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	208088	Hydrochlorothiazide 25 MG / Reserpine 0.125 MG Oral Tablet [Hydroserpine]
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	208089	Hydrochlorothiazide 25 MG / Reserpine 0.125 MG Oral Tablet [Mallopress]
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	208090	Hydrochlorothiazide 50 MG / Reserpine 0.125 MG Oral Tablet [Hydro-Reserp]
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	208092	Hydrochlorothiazide 50 MG / Reserpine 0.125 MG Oral Tablet [Hydroserp]
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	208093	Hydrochlorothiazide 50 MG / Reserpine 0.125 MG Oral Tablet [Hydroserpine]
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	208085	Hydropres-25 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	208091	Hydropres-50 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	977950	Amiloride Hydrochloride 2.5 MG / Hydrochlorothiazide 25 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	977883	amiloride hydrochloride 5 MG / HCTZ 50 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	977885	Moduretic 5-50 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	198224	HCTZ 25 MG / spironolactone 25 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	198225	HCTZ 50 MG / spironolactone 50 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	208112	Aldactazide 25 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	208116	Aldactazide 50 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	208113	Hydrochlorothiazide 25 MG / Spironolactone 25 MG Oral Tablet [Spironolactone Plus]
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	314029	HCTZ 25 MG / triamterene 50 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	198316	HCTZ 25 MG / triamterene 37.5 MG Oral Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	310812	HCTZ 25 MG / triamterene 37.5 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	198314	HCTZ 25 MG / triamterene 50 MG Oral Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	310818	HCTZ 50 MG / triamterene 75 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	208124	Dyazide (HCTZ 25 MG / triamterene 37.5 MG) Oral Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	93253	Maxzide-25 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	93252	Maxzide-50 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	237192	Chlorothiazide 250 MG / Reserpine 0.125 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197477	Chlorothiazide 500 MG / Reserpine 0.125 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	213504	Chlorothiazide 250 MG / Reserpine 0.125 MG Oral Tablet [Diupres-250]
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	213505	Chlorothiazide 500 MG / Reserpine 0.125 MG Oral Tablet [Diupres-500]
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	205364	Chlorthalidone 25 MG / Reserpine 0.125 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	205365	Chlorthalidone 50 MG / Reserpine 0.25 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	214094	Chlorthalidone 25 MG / Reserpine 0.125 MG Oral Tablet [Demi-Regroton]
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	214095	Chlorthalidone 50 MG / Reserpine 0.25 MG Oral Tablet [Regroton]
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197382	Atenolol 100 MG / Chlorthalidone 25 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	152916	Atenolol 50 MG / Chlorthalidone 12.5 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197383	Atenolol 50 MG / Chlorthalidone 25 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	746023	Tenoretic 100 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	746030	Tenoretic 50 Oral Tablet

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866842	Atenolol 25 MG / Metoprolol Tartrate 25 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	199717	Cloпамide 5 MG / Pindolol 10 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898342	Amlodipine 10 MG / Benazepril hydrochloride 20 MG Oral Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898346	Amlodipine 10 MG / Benazepril hydrochloride 40 MG Oral Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898350	Amlodipine 2.5 MG / Benazepril hydrochloride 10 MG Oral Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898353	Amlodipine 5 MG / Benazepril hydrochloride 10 MG Oral Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898356	Amlodipine 5 MG / Benazepril hydrochloride 20 MG Oral Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898359	Amlodipine 5 MG / Benazepril hydrochloride 40 MG Oral Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898344	Lotrel 10/20 Oral Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898348	Lotrel 10/40 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898352	Lotrel 2.5/10 Oral Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898355	Lotrel 5/10 Oral Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898358	Lotrel 5/20 Oral Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898361	Lotrel 5/40 Oral Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	858618	Enalapril Maleate 5 MG / Felodipine 2.5 MG Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	858621	Enalapril Maleate 5 MG / Felodipine 5 MG Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	858884	Lexxel 5/2.5 Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	858892	Lexxel 5/5 Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	854993	Indapamide 1.25 MG / Perindopril Erbumine 4 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	389180	Felodipine 2.5 MG / Ramipril 2.5 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	389181	Felodipine 5 MG / Ramipril 5 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897781	trandolapril 1 MG / verapamil hydrochloride 240 MG 24 HR Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897778	trandolapril 1 MG / Verapamil hydrochloride 240 MG Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897783	trandolapril 2 MG / verapamil hydrochloride 180 MG 24 HR Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	901451	trandolapril 2 MG / Verapamil hydrochloride 180 MG Extended Release Capsule
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897786	trandolapril 2 MG / Verapamil hydrochloride 180 MG Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897844	trandolapril 2 MG / verapamil hydrochloride 240 MG 24 HR Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897847	trandolapril 2 MG / Verapamil hydrochloride 240 MG Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897853	trandolapril 4 MG / Verapamil hydrochloride 240 MG 24 HR Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897856	trandolapril 4 MG / Verapamil hydrochloride 240 MG Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897782	Tarka 1/240 24 HR Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897785	Tarka 2/180 24 HR Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897846	Tarka 2/240 24 HR Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897855	Tarka 4/240 24 HR Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897780	trandolapril 1 MG / Verapamil hydrochloride 240 MG Extended Release Tablet [Tarka 1/240]

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897787	trandolapril 2 MG / Verapamil hydrochloride 180 MG Extended Release Tablet [Tarka 2/180]
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897848	trandolapril 2 MG / Verapamil hydrochloride 240 MG Extended Release Tablet [Tarka 2/240]
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897857	trandolapril 4 MG / Verapamil hydrochloride 240 MG Extended Release Tablet [Tarka 4/240]
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	999986	Amlodipine 10 MG / Hydrochlorothiazide 12.5 MG / Olmesartan medoxomil 40 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	999991	Amlodipine 10 MG / Hydrochlorothiazide 25 MG / Olmesartan medoxomil 40 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	730861	Amlodipine 10 MG / Olmesartan medoxomil 20 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	730866	Amlodipine 10 MG / Olmesartan medoxomil 40 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	999967	Amlodipine 5 MG / Hydrochlorothiazide 12.5 MG / Olmesartan medoxomil 20 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	999996	Amlodipine 5 MG / Hydrochlorothiazide 12.5 MG / Olmesartan medoxomil 40 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	1000001	Amlodipine 5 MG / Hydrochlorothiazide 25 MG / Olmesartan medoxomil 40 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	730869	Amlodipine 5 MG / Olmesartan medoxomil 20 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	730872	Amlodipine 5 MG / Olmesartan medoxomil 40 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	744624	Azor 10/20 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	744628	Azor 10/40 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	744632	Azor 5/20 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	744636	Azor 5/40 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	999971	Tribenzor 20/5/12.5 (olmesartan medoxomil / amlodipine (as amlodipine besylate) / HCTZ) Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	999990	Tribenzor 40/10/12.5 (olmesartan medoxomil / amlodipine (as amlodipine besylate) / HCTZ) Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	999995	Tribenzor 40/10/25 (olmesartan medoxomil / amlodipine / HCTZ) Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	1000000	Tribenzor 40/5/12.5 (olmesartan medoxomil / amlodipine (as amlodipine besylate) / HCTZ) Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	1000005	Tribenzor 40/5/25 (olmesartan medoxomil / amlodipine (as amlodipine besylate) / HCTZ) Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	876514	Amlodipine 10 MG / telmisartan 40 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	876519	Amlodipine 10 MG / telmisartan 80 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	876524	Amlodipine 5 MG / telmisartan 40 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	876529	Amlodipine 5 MG / telmisartan 80 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	876518	Twynsta 40/10 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	876528	Twynsta 40/5 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	876523	Twynsta 80/10 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	876533	Twynsta 80/5 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	1011718	aliskiren 150 MG / valsartan 160 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	1011729	aliskiren 300 MG / valsartan 320 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	722126	Amlodipine 10 MG / valsartan 160 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	722131	Amlodipine 10 MG / valsartan 320 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	722134	Amlodipine 5 MG / valsartan 160 MG Oral Tablet

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	722137	Amlodipine 5 MG / valsartan 320 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	848131	amlodipine 10 MG / HCTZ 12.5 MG / valsartan 160 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	848151	amlodipine 10 MG / HCTZ 25 MG / valsartan 160 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	848135	amlodipine 10 MG / HCTZ 25 MG / valsartan 320 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	848140	amlodipine 5 MG / HCTZ 12.5 MG / valsartan 160 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	848145	amlodipine 5 MG / HCTZ 25 MG / valsartan 160 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	1011735	Valturna (aliskiren 300 MG / valsartan 320 MG) Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	1011724	Valturna (aliskiren 150 MG / valsartan 160 MG) Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	848149	Exforge HCT 5/160/25 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	848144	Exforge HCT 5/160/12.5 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	848139	Exforge HCT 10/320/25 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	848155	Exforge HCT 10/160/25 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	848134	Exforge HCT 10/160/12.5 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	724879	Exforge 10/160 Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	724895	Exforge (amlodipine 5 MG / valsartan 320 MG) Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	724891	Exforge (amlodipine 5 MG / valsartan 160 MG) Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	724887	Exforge (amlodipine 10 MG / valsartan 320 MG) Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	833237	Diltiazem Hydrochloride 180 MG / Enalapril Maleate 5 MG Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	846148	Teczem Extended Release Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	389180	Felodipine 2.5 MG / Ramipril 2.5 MG Oral Tablet
000262	HTN	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	389181	Felodipine 5 MG / Ramipril 5 MG Oral Tablet
000201	HTN	1	E	Postural Hypotension	Diagnosis/Condition/Problem	I9	458.0	Orthostatic hypotension; includes postural
000201	HTN	1	E	Postural Hypotension	Diagnosis/Condition/Problem	I9	458.8	Other specified hypotension
000201	HTN	1	E	Postural Hypotension	Diagnosis/Condition/Problem	I9	458.9	Hypotension, unspecified
000201	HTN	1	E	Postural Hypotension	Diagnosis/Condition/Problem	I10	G90.3	Neurogenic orthostatic hypotension (Shy-Drager)
000201	HTN	1	E	Postural Hypotension	Diagnosis/Condition/Problem	I10	I95.1	Orthostatic hypotension
000201	HTN	1	E	Postural Hypotension	Diagnosis/Condition/Problem	I10	I95.2	Hypotension due to drugs
000201	HTN	1	E	Postural Hypotension	Diagnosis/Condition/Problem	SNM	28651003	orthostatic hypotension
000201	HTN	1	E	Postural Hypotension	Diagnosis/Condition/Problem	SNM	75181005	chronic orthostatic hypotension
000201	HTN	1	E	Postural Hypotension	Diagnosis/Condition/Problem	SNM	84438001	pure autonomic failure
000201	HTN	1	E	Postural Hypotension	Diagnosis/Condition/Problem	SNM	61933008	hyperadrenergic postural hypotension
000201	HTN	1	E	Postural Hypotension	Diagnosis/Condition/Problem	SNM	70247006	hypoadrenergic postural hypotension
000201	HTN	1	E	Postural Hypotension	Diagnosis/Condition/Problem	SNM	371073003	postural orthostatic tachycardia syndrome
000201	HTN	1	E	Postural Hypotension	Diagnosis/Condition/Problem	SNM	230664009	sympathotonic orthostatic hypotension
000160	HTN	1	E	Medical reason	Negation Rationale	HL7	21745	
000160	HTN	1	E	Medical reason	Negation Rationale	HL7	21747	
000160	HTN	1	E	Medical reason	Negation Rationale	HL7	21703	
000160	HTN	1	E	Medical reason	Negation Rationale	HL7	21704	
000160	HTN	1	E	Medical reason	Negation Rationale	HL7	22855	
000160	HTN	1	E	Medical reason	Negation Rationale	HL7	21990	

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000160	HTN	1	E	Medical reason	Negation Rationale	HL7	21738	
000160	HTN	1	E	Medical reason	Negation Rationale	HL7	22259	
000160	HTN	1	E	Medical reason	Negation Rationale	HL7	21815	
000160	HTN	1	E	Medical reason	Negation Rationale	HL7	22261	
000174	HTN	1	E	Patient reason	Negation Rationale	HL7	19729	
000174	HTN	1	E	Patient reason	Negation Rationale	HL7	21741	
000174	HTN	1	E	Patient reason	Negation Rationale	HL7	21746	
000174	HTN	1	E	Patient reason	Negation Rationale	HL7	21743	
000174	HTN	1	E	Patient reason	Negation Rationale	HL7	21710	
000174	HTN	1	E	Patient reason	Negation Rationale	HL7	21708	
000174	HTN	1	E	Patient reason	Negation Rationale	HL7	22851	
000174	HTN	1	E	Patient reason	Negation Rationale	HL7	14880	
000174	HTN	1	E	Patient reason	Negation Rationale	HL7	22260	
000174	HTN	1	E	Patient reason	Negation Rationale	HL7	15985	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	22168	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	22169	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	22165	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	22166	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	22167	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	21493	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	19731	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	19730	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	19733	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	19735	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	19734	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	19736	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	21744	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	22024	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	22023	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	21706	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	21709	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	21707	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	21732	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	21706	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	21731	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	21733	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	21728	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	21729	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	21730	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	21734	

**AMA-PCPI Level I EHR Specifications
Hypertension - Blood Pressure Control (HTN-1)**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Standard Taxonomy	Code	Code Description
000200	HTN	1	E	System Reason	Negation Rationale	HL7	22867	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	21735	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	22866	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	22865	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	21568	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	21408	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	22907	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	22909	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	22911	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	22913	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	22912	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	22858	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	22857	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	22859	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	19989	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	19990	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	19988	
000200	HTN	1	E	System Reason	Negation Rationale	HL7	19987	

This Physician Performance Measurement Set (PPMS) and related data specifications were developed by the Physician Consortium for Performance Improvement (the Consortium) including the American College of Cardiology (ACC), the American Heart Association (AHA) and the American Medical Association (AMA) to facilitate quality improvement activities by physicians. The performance measures contained in this PPMS are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications. This PPMS is intended to assist physicians to enhance quality of care and is not intended for comparing individual physicians to each other or for individual physician accountability by comparing physician performance against the measure or guideline.

This PPMS is subject to review and may be revised or rescinded at any time by the Consortium. The PPMS may not be altered without the prior written approval of the Consortium. A PPMS developed by the Consortium, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the performance measures for commercial gain, or incorporation of the performance measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the performance measures require a license agreement between the user and the AMA, (on behalf of the Consortium) or the ACC or the AHA. Neither the Consortium nor its members shall be responsible for any use of this PPMS.

THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.

© 2009 American College of Cardiology, American Heart Association and American Medical Association. All Rights Reserved.

Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, the ACC, the AHA, the Consortium and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

CPT® contained in the measures specifications is copyright 2005 American Medical Association. LOINC® copyright 2004 Regenstrief Institute, Inc. SNOMED CLINICAL TERMS (SNOMED CT®) copyright 2004 College of American Pathologists (CAP). All Rights Reserved. Use of SNOMED CT® is only authorized within the United States.

PCPI Performance Measure Testing Results - Hypertension

The PCPI Testing Protocol outlines the comprehensive set of tests that should be conducted in different practice settings, using different data sources, for each performance measurement set. The PCPI recognizes that multiple testing projects will be needed to achieve the required test results for each measurement set. Moreover, testing and surveillance should be part of continued evaluation and updating of the measures.

This document presents results for the American College of Cardiology (ACC)/ American Heart Association (AHA)/ PCPI Hypertension Physician Performance Measures from the Doctor's Office Quality Project¹, the CMS Physician Group Practice program², the Persell testing project³, the Peterson testing project⁴, and the EQUIP Project.

1. Where are the measures used and what are the documented performance rates ?

Performance rates for individual measures are found to vary across the measure reporting and testing programs. This is expected, in that the performance rates are derived from different data sources, different practice sites, and variation in both the program implementation of the measures and approaches to implementation of the measures at individual practices or by the physicians in the practice sites included in the testing project. Variation in performance rates across practice sites suggests that the measure is able to differentiate among practices. In addition, no single relatively high value of performance for a measure should be used as an indication of that measure being "topped out", and hence no longer important or meaningful to measure.

PCPI #	NQF endorsed (#)	Measure	Doctor's Office Quality (DOQ) Project (performance)	CMS PGP 2006 (performance)	Persell Testing Project (performance)	Petersen Testing Project (performance)	EQUIP Project (performance)
1	13	Blood Pressure Measurement	79.7 %	Not reported	Surrogate testing*	Surrogate testing* 57.3 % were in control	Not reported
2	17	Plan of Care	Not reported	Not reported	Surrogate testing*	Surrogate testing* 53.7 % had a follow-up visit within 6 months	Not reported

* Surrogate testing refers to testing measures, and the corresponding data elements (eg, numerators and denominators), that are similar to those in the PCPI measures.

What are the reported exception rates? (# patients with valid exceptions / (# patients in denominator)

It is expected that reported exception rates will vary across measures and across the measure reporting and testing programs. This is primarily due to differences in the types of measure (eg, medications versus screening), data sources examined in testing, variation among the practice sites where the measures were implemented, and the types and number of reasons included in the measure specification (ie, medical reason, patient reason, and system reason). Any one value for a reported exception rate, in of itself, should not be interpreted as indication of gaming or patient selection behavior.

Measure	
Blood Pressure Measurement	This measure has no exceptions.
Plan of Care	This measure has no exceptions.

¹ DOQ and DOQ-IT measure specifications. Available at: <https://www.cms.hhs.gov/apps/OMIS/browseResults.asp?bItem=ProgramId&bid=3&pageNum=2>

² http://www.cms.gov/DemoProjectsEvalRpts/downloads/PGP_Fact_Sheet.pdf

³ Persell SD, Kho AN, Thompspon JA, Baker DW. Improving Hypertension Quality Measurement Using Electronic Health Records. Medical Care. Volume 47(4), April 2009, pp 388-394

⁴ Peterson LA, Woodard LD, Henderson LM, Urech TH, Pietz K. Will Hypertension Performance Measures Used for Pay-for-Performance Programs Penalize Those Who Care for Medically Complex Patients? Circulation, 2009;119:2978-2985.

PCPI Performance Measure Testing Results - Hypertension

2. Which tests have been carried out in which settings or data sources? Tests of feasibility/ implementation, reliability, validity, and unintended consequences conducted in a variety of practice settings including (eg solo practices, large practices, academic practices, safety-net practices, single- and multi-specialty groups).

Setting Data Source	Medical Record (Gold Standard) (Paper or Electronic)	EHR Reporting	Registry	Administrative Data (single source)	Administrative Data (multiple sources)	Administrative Data Plus Clinical Data
Solo Practice						
Specialty Practice	<ul style="list-style-type: none"> • Feasibility • Inter-Rater Reliability 	<ul style="list-style-type: none"> • Feasibility • Inter-Rater Reliability 				
Safety-net practice						
Academic Setting	<ul style="list-style-type: none"> • Feasibility 	<ul style="list-style-type: none"> • Feasibility • Inter-Rater Reliability 				
Community Setting	<ul style="list-style-type: none"> • Feasibility • Inter-Rater Reliability 	<ul style="list-style-type: none"> • Feasibility • Inter-Rater Reliability 				

<p>Feasibility Testing</p>	<p>3. How confident are we that practices can accurately collect and report these measures in a sustainable fashion?</p> <p>These measures have been tested and found to be generally feasible in paper, EHR, and claims data sources.</p> <p>The feasibility of a PCPI performance measure/measure set refers to:</p> <ul style="list-style-type: none"> • Whether or not data are stored in a codified field • Which clinical codes sets are utilized/available • Where in the record the data are found • Necessary clarifications needed to implement the measure • Documentation of challenges to measure implementation • The extent to which clinical practices are able to interpret measure definitions and technical specifications, and a) integrate them into existing workflows and health information systems to collect, manage, and manipulate data elements; b) compute performance measures; and c) generate performance reports within a reasonable time frame and budget. <p>Doctor’s Office Quality Pilot Project</p> <p><u>Data Source:</u> 2 practices sites with electronic health records</p> <p><u>Methods</u> Practices were given technical specifications to use to capture the quality measures from their EHR system Feasibility was assessed for all measures, and some measures were implemented</p> <p><u>Results</u> Both sites found both measures to be fully feasible.</p> <p>CMS PGP Demonstration Project</p> <p><u>Data Source:</u> 10 physician group practices sites with electronic health records Represents 5,000 physicians and 220,000 Medicare fee-for-service beneficiaries</p>
-----------------------------------	--

PCPI Performance Measure Testing Results - Hypertension

	<p><u>Methods</u> Practices were given technical specifications to use to capture the quality measures from their EHR system Feasibility was assessed for all measures, and measures were implemented in a phased approach</p> <p><u>Results</u> At the end of the third performance year, all 10 of the participating physician groups continued to improve the quality of care for patients with chronic illness or who require preventive care by achieving benchmark or target performance on at least 28 out of 32 quality markers for patients with diabetes, coronary artery disease, congestive heart failure, hypertension, and cancer screening. Two of the physician groups -- Geisinger Clinic and Park Nicollet Health Services -- achieved benchmark quality performance on all 32 quality measures.</p> <p>EQUIP Project <u>Data Source:</u> Four multiple site HRSA-funded Community Health Centers with electronic health records</p> <p><u>Methods</u> Practices were given technical specifications to use to capture the quality measures from their EHR system Feasibility was assessed for all measures</p> <p><u>Results</u> The site found both measures to be fully feasible.</p> <p>Persell Hypertension Quality Measure Project <u>Data Source:</u> Electronic health records for 5905 hypertensive adults with 3 or more clinic visits at an internal medicine clinic</p> <p><u>Methods</u> Cross sectional study Measured simple blood pressure control as the proportion of diagnosed hypertension patients with their last blood pressure below goal Compared simple control to sequentially more complex measures</p> <p><u>Results</u> It is possible to collect information on hypertension performance measures from electronic health records.</p> <p>Petersen Hypertension Quality Measure Project <u>Data Source:</u> Electronic health records for 141609 hypertensive veterans</p> <p><u>Methods</u> Blood pressure, overall good quality of care, and patient satisfaction of care were assessed Patients were grouped based on co morbidities The relationship between patient assessment and objective measures of quality were assessed</p> <p><u>Results</u> It is possible to collect information on hypertension performance measures Contrary to expectation, patients with greater complexity had higher odds of receiving high-quality care for hypertension</p>
<p>Reliability Testing</p>	<p>4. How confident are we that the measures accurately and consistently assess the performance of physicians providing the care assessed in the measure?</p> <p>Reliability is whether two abstractors, reviewing the same data from the same data source, would come to the same conclusion as to the patient meeting the measure, not meeting the measure, or</p>

PCPI Performance Measure Testing Results - Hypertension

qualifying as an exception.

Doctor's Office Quality Pilot Project

Data Source:

2 practices sites with electronic health records

Methods

Abstractor responses were compared with “gold standard” responses determined by two abstractors familiar with the data definitions and who were responsible for abstractor training.

Results

Measure	Doctor's Office Quality (DOQ) Project
Blood Pressure Measurement	389 / 400 97 % 33 / 35 94 %
Plan of Care	263 / 271 97 % 14 / 15 93 %

Measure Exceptions Validated

(and specific exception reasons documented to inform measure maintenance)

5. Are exceptions clinically appropriate and consistently documented?

These measures have no exceptions.

Comparison of Data Sources

*Note: in these projects it is recommended to always compare the secondary data source to the current gold standard of manual abstraction of the medical record.

6. Is measure collection from different data sources comparable?

This test has not yet been performed for this measure set.

7. How does automated measure calculation compare to manual measure abstraction?

This test has not yet been performed for this measure set.

8. If automated reporting identifies a patient as meeting the measure, what likelihood is there that manual review will validate that finding?

This test has not yet been performed for this measure set.

9. Are the individual parts of the measure (numerator, denominator, exceptions) reliably calculated, as compared to the overall measure?

This test has not yet been performed for this measure set.

10. What proportion of patients that met the measure are correctly identified?

- Insufficient sample size to conduct this test

11. What proportion of patients that do not meet the measure are correctly identified?

- Insufficient sample size to conduct this test

EHR “In Silo” Verification

Note: initially this may be of limited

12. Can EHR products reliably identify data elements and calculate these measures?

A “dummy” data set of patient data will be provided to several EHR vendors along with EHR measure specifications. The vendors will use this test file to determine if their system can reliably calculate the measures based on intended documentation patterns.

PCPI Performance Measure Testing Results - Hypertension

usefulness until EHR functionality and use progresses	This test has not yet been performed for this measure set.
Predictive Validity	<p>13. Does high performance on these measures lead to better patient outcomes?</p> <p>If the scientific evidence regarding the process of care is strong and widely accepted in the field, no formal evaluation of predictive validity is necessary. If the evidence is less strong, however, it is desirable to show that high performance leads to better patient outcomes.</p> <p>This test has not yet been performed for this measure set.</p>
Unintended Consequences	<p>14. Have monitoring and testing uncovered unexpected consequences of measurement?</p> <p>Testing should be performed for anticipated unintended consequences. Unanticipated unintended consequences should be monitored for on a long term basis as they may only occur in later stages and widespread adoption.</p> <p>This test has not yet been performed for this measure set.</p>
Project Descriptions	<p>Doctor's Office Quality Pilot Project Data was captured at two large physician practice groups who use two distinct EHR systems. The study population of group 1 was their fee-for service Medicare patients. The study population was all non-Medicare patients for Group 2. Once the DOQ clinical measures were developed, the practices were given technical specifications to use to capture the quality measures from their EHR system. Feasibility was assessed for all measures, and some measures were implemented. DOQ and DOQ-IT measure specifications. Available at: https://www.cms.hhs.gov/apps/QMIS/browseResults.asp?bItem=ProgramId&bID=3&pageNum=2</p> <p>CMS PGP Demonstration Project CMS Physician Group Practice Project. Available at: http://www.cms.hhs.gov/DemoProjectsEvalRpts/downloads/PGP_Fact_Sheet.pdf The ambulatory care measures used under the demonstration are part of Medicare's comprehensive efforts to improve the quality of care delivered to Medicare beneficiaries. CMS worked with the physician groups to develop a consensus agreement on how to report the measures and how to use them to assess performance and reward quality under the demonstration. The measures were phased in starting with the diabetes mellitus measures that were used to assess performance and reward quality care during the first performance year. Additional measures focusing on congestive heart failure and coronary artery disease were added in performance year two. Hypertension and cancer screening measures were added for performance years three, four and five.</p> <p>Persell Testing Project The objective of this cross-sectional study was to compare measured quality using simple outcome measures to more sophisticated measures utilizing data available within an electronic health record. A total of 5905 hypertensive adults with 3 or more clinic visits between July 1, 2005 and December 31, 2006 at an internal medicine clinic were eligible for the study. The study measured simple control as the proportion of diagnosed hypertension patients with their last blood pressure below goal. We compared this to sequentially more complex measures. Persell SD, Kho AN, Thompspon JA, Baker DW. Improving Hypertension Quality</p>

PCPI Performance Measure Testing Results - Hypertension

Measurement Using Electronic Health Records. *Medical Care*. Volume 47(4), April 2009, pp 388-394.

Petersen Testing Project

This project classified 141609 veterans with hypertension into 4 condition groups: those with hypertension-concordant (diabetes mellitus, ischemic heart disease, dyslipidemia) and/or – discordant (arthritis, depression, chronic obstructive pulmonary disease) conditions or neither. We measured blood pressure control at the index visit, overall good quality of care for hypertension, including a follow-up interval, and patient ratings of satisfaction with their care. Associations between condition type and number of coexisting conditions on receipt of overall good quality of care were assessed with logistic regression. The relationship between patient assessment and objective measures of quality was assessed.

Peterson LA, Woodard LD, Henderson LM, Urech TH, Pietz K. Will Hypertension Performance Measures Used for Pay-for-Performance Programs Penalize Those Who Care for Medically Complex Patients? *Circulation*, 2009;119:2978-2985.

EQUIP Project

The project aim was to implement advanced EHR functionality, including decision support, care management, and quality reporting of national performance measures in a replicable, scalable model across four safety net Health Centers. The project was carried out in four multiple site HRSA-funded Community Health Centers desiring to leverage health information technology to support their application of the IHI Care model. Methodology included working with vendor, measure developers, and end users to define necessary data elements for incorporation into end user screens, report specifications in a data warehouse for national performance measure reporting and progressive refinement of replicable implementation methodology to drive standardized adoption and use through sequential pilots. A formal evaluation combined implementation monitoring with process and outcome measures. All major goals and objectives were achieved. The Data Warehouse supports regular reporting on national performance measures and aspects of system use at network, site, and individual provider level.